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1. Summary 
 
Since its first description in 1994 by Yuan Chang and Patrick Moore, Kaposi’s sarcoma-
associated herpesvirus (KSHV) or Human Herpesvirus 8 (HHV-8) has emerged as a 
pathogen of international public health importance. KSHV belongs to the γ-herpesvirinae 
subfamily and shows similarity to EBV (Epstein - Barr Virus) and HVS (Herpesvirus 
saimiri). It has been detected in biopsies of all forms of Kaposi’s sarcoma (KS), 
irrespective of geographic origin, age, or gender of the patient13. Moreover, KSHV has 
been shown to be associated with two other diseases, multicentric Castleman’s disease 
(MCD) and primary effusion lymphoma (PEL). 
In comparison to α and β-herpesvirinae, the understanding of KSHV-related 
pathogenesis has been hampered by inefficient virus replication in vitro, poor cell culture 
systems and the lack of an animal model. Thus, many basic questions concerning the 
biology of KSHV infection remain open. For example, the primary target cell of KSHV 
and the function of more than 50% of the viral proteins are still unknown. Since the 
investigation of viral gene functions by virus mutants did not prove to be very efficient for 
KSHV, a system for a genome-wide screening of viral gene functions by cloning the 
complete KSHV ORFeome (all open reading frames) and by generating KSHV arrays in 
a variety of different expression vectors was established in this project.  
The intimate relationship between viruses and their host cells dictates that viruses 
exploit key cellular regulatory systems and usurp important cellular processes to carry 
out a successful infection. Very often they regulate cellular signalling pathways, which 
favour viral infection and replication in the host cells. In cells infected with KSHV, the 
activation of the serum response element (SRE) is crucial for virus infection. The SRE is 
a transcription factor binding site present in promoters of many genes involved in cell 
growth and transformation. In this study, a genome-wide screen for KSHV genes 
inducing the SRE element and AP-1 was performed. A strong induction of SRE by the 
latency-associated nuclear antigen 1 (LANA-1) was observed. LANA-1 is a 
multifunctional protein which interacts with the p53 and RB tumor suppressor proteins. 
LANA-1 is mandatory for the maintenance of viral episomes. This study reveals several 
novel functions of LANA-1. It was found that LANA-1 also stimulated the interferon-
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stimulated response element (ISRE) present in promoters activated by type I interferons. 
LANA-1 led to an activation of the ERK-1/2 MAP kinase, but also bound to the Mediator, 
a multi-subunit transcriptional coactivator complex for RNA polymerase II, via the 
ARC92/ACID1 subunit. Since LANA-1 interacted with SRF, one of the two transcription 
factors binding to the bipartite SRE element, a model for LANA-1 as an adaptor between 
specific transcription factors and the basal transcriptional machinery was hypothesized. 
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2. Introduction 
 
2.1. Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) 
Classical Kaposi’s sarcoma (KS) was originally described in 1872 by the Hungarian 
dermatologist Moritz Kaposi as an idiopathic, multi-pigmented sarcoma of the skin16. For 
more than a century, KS remained an interesting neoplasm for only a few clinicians due 
to its rare occurrence and very restricted outbreaks primarily in Mediterranean white 
men. In addition, this complex proliferative lesion slowly progresses and presents with 
only mild clinical manifestation. The explosion of the AIDS epidemic around the mid 
1980s brought increased attention to KS as it is the major malignancy among AIDS 
patients, occurring in approximately 20% of male HIV patients136. The strong linkage 
between KS and HIV initially led researchers to suspect HIV as the single etiological 
cause for KS. The hunt for the causative agent came to an end and shifted to a new 
stage when Drs Chang and Moore discovered fragments of DNA specific to KS lesions 
that were similar to other known herpesviruses including herpesvirus saimiri (HVS) and 
Epstein-Barr virus (EBV)32,33. This new herpesvirus named Kaposi’s sarcoma-associated 
herpesvirus (KSHV) or Human Herpesvirus 8 (HHV-8) was soon found in all 
epidemiological forms of KS, and defined as an etiological agent of KS13,37,112. This 
discovery opened new avenues in the research on, therapy for, and prevention of KS. 
 
2.1.1. KSHV – associated diseases 
KSHV is etiologically linked to Kaposi’s sarcoma, which is of endothelial origin, and two 
lymphoproliferative disorders, “body cavity-based” or “primary effusion lymphoma” 
(BCBL/PEL) and multicentric Castleman’s disease (MCD) (Fig. 1). 
 
2.1.1.1. Kaposi’s sarcoma (KS) - clinical and morphological features, 
epidemiology 
Usually classical KS first manifests as bluish-red, well demarcated, painless maculae on 
distal portions of the lower limbs. These KS early patches and plaque lesions often 
resemble granulated tissues. In the majority of instances the lesions progress slowly and 
merge into large plaques. However, solitary lesions occasionally progress to form 
nodular and fungi-form, brownish-red tumors35. During long-lasting courses of KS, the 
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lesions may erode, bleed, and even ulcerate. In addition to the skin, KS manifestation 
can involve mucosal surfaces, especially in the oral cavity and gastrointestinal tract. 
Involvement of internal organs is infrequent in classical KS and occurs in only 
approximately 10% of cases153,154. Paracrine effects play an important role in the 
pathogenesis of this tumor, as tumor tissue contains high concentrations of inflammatory 
cytokines (e.g. IL-6, IL-10) and growth factors (e.g. VEGF, bFGF)28. The KS lesions 
contain spindle cells that share features with endothelial cells and smooth muscle 
cells118. The vast majority of spindle cells is latently infected and expresses a small 
subgroup of viral proteins including Lana-1, v-IRF3 (Lana-2), v-cyclin, v-FLIP and 
kaposin A45,78. Most other viral proteins are expressed by lytically infected cells 
constituting less than 1% of the tumor.  
KS can be classified into four distinct clinical varieties: classical, endemic (African), 
iatrogenic (immunosuppression-associated), and AIDS-associated (epidemic). Classical 
KS typically arises in elderly men of Mediterranean and eastern European Jewish 
decent and presents as indolent disease with paranodular skin lesions with little or no 
visceral involvement113. Endemic KS is widespread in southern equatorial Africa among 
young black adult males and prepubescent children, systemic involvement can occur 
and disease progression is often rapid97. Iatrogenic immunosuppression-associated KS 
includes corticosteroid-induced KS and post-transplant KS and gives rise to systemic 
involvement47,58. AIDS-associated KS is the most aggressive form, lesions occurring 
both on the skin and the viscera, with variable disease progression158. Epidemiological 
evidence has suggested that all forms of KS have an infectious etiology158. 
Geographic location, ethnicity, age, and gender heavily influence the incidence rate of 
classical KS. Low rates were reported in England and Wales (0.14 per million in both 
males and females between 1971-1980)62, intermediate rates were reported in Sweden 
(4.0 per million in men and 1.4 per million in women between 1952-1982)42, whereas 
higher rates were reported in Italy (10.5 per million in men and 2.7 per million in women 
between 1976-1984)53, and Greece (5.8 per million in men and 3.7 per million in women 
between 1979-1983)155. The incidence rate of classic KS in Israeli Arabs (7 per million 
and 2 per million in men and women, respectively) was 3-fold lower than Israeli Jews73. 
KS was reported to occur more frequently in individuals during their fifth and sixth 
decades of life, with a lower incidence at other ages and only sporadic cases occurring 
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before the age of thirty70. The higher incidence of KS among men compared to women 
suggests that gender is a risk factor for KS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: KSHV-associated diseases as a side effect of viral persistence.  
Transmission of Kaposi’s sarcoma–associated herpesvirus (KSHV) leads to a lifelong infection, 
in which the virus remains latent in cellular reservoirs. Reactivation of the virus leads to the 
infection of new cells within the host and secretion in saliva, and thus, possibly, transmission of 
the virus. In a minority of infected persons, and often in the setting of immunodeficiency, KSHV-
associated diseases may arise. These result from the production of viral proteins, which in turn 
may induce cellular growth factors and angiogenic factors. Infected cells may also contain the 
Epstein–Barr virus and cellular genetic alterations (second genetic “hits”). Histologic images of 
the three diseases for which a causal association with KSHV has been firmly established are 
shown: multicentric Castleman’s disease (lymph-node specimen; hematoxylin and eosin, x200), 
Kaposi’s sarcoma (skin specimen; hematoxylin and eosin, x200), and primary effusion 
lymphoma (pleural fluid; hematoxylin and eosin, x1000) (adapted from Cesarman, 2003)27. 
 
 
The frequency of KS in HIV disease is strikingly higher in homosexual or bisexual males 
than in patients with haemophilia, transfusion recipients or injecting drug users11,66. 
Classical KS is more common in non-HIV-infected homosexual men than the general 
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population, suggesting transmission of an infectious etiological agent via sexual routes 
or close fecal contact10. 
 
2.1.1.2. Primary effusion lymphoma (PEL) 
PEL is a rare lymphoma which occurs in the peritoneal, pleural or pericardial space, 
often in the absence of an obvious tumor mass51. The lymphoma cells have usually 
monoclonal and B cell origin with pleomorphic and anaplastic features, and express only 
few of the usual markers of B cell differentiation25,132. In most PEL cases, the lymphoma 
cells are co-infected with Epstein-Barr virus (EBV)24,29. EBV is present in PEL cells in a 
“monoclonal” form, i.e. EBV episomes in different lymphoma cells all have the identical 
terminal repeat pattern, indicating that infection by a single EBV particle preceded the 
emergence of the malignant clonal lymphoma137. Immunohistochemistry and in situ 
hybridisation studies on several PEL cell lines indicate that five KSHV genes, LANA-1, v-
cyclin, v-FLIP, kaposin, LANA-2, are expressed in a substantial proportion of lymphoma 
cells45,105,122,134,162.  
 
2.1.1.3. Multicentric Castleman’s disease (MCD) 
MCD is a lymphoproliferative disease found in the mediastinum, mesenterial or 
peripheral lymph nodes and is characterized histologically by expanded germinal 
centres with B cell and vascular proliferation137. MCD in AIDS patients is often 
associated with Kaposi’s sarcoma. KSHV can nearly always be detected by PCR in the 
lymph nodes or spleen affected by MCD in AIDS patients, but is much less common in 
Castleman’s disease without HIV infection44,145. KSHV-infected B cells express, as 
assessed by immunohistochemistry, LANA-1, a hallmark of all KSHV-infected 
cells44,45,78. MCD is associated with interleukin-6 (IL-6) overexpression1.  
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2.1.2. KSHV virion structure 
KSHV shows the typical morphology of herpesviruses. The virus particle has a diameter 
of approximately 125 nm (1250 A°)125,161. The core of the mature virion contains the viral 
DNA in the form of a torus. The capsid has an icosahedral shape and consists of 162 
hexagonal capsomers. Three types of capsids A, B and C are released from PEL cells 
after TPA or sodium butyrate treatment. C-capsids are fully mature capsids and contain 
the polypeptide ORF25/MCP (major capsid protein), ORF65/SCIP (small capsomer 
interacting protein), ORF26/TRI-2 (triplex-2), ORF62/TRI-1 and the 160- to 170-kb viral 
genome. They have a total mass of approximately 300 megadaltons110. A and B capsids 
contain the four proteins listed above but lack viral genomic DNA. 
The envelope has a typical trilaminar appearance and contains glycoproteins and lipids. 
The tegument consisting of various viral and cellular proteins is located between the 
capsid and the envelope (Fig. 2). 
 
               
Fig. 2: The herpesvirus particle.  
Schematic model of a herpesvirus particle (adapted from Reschke, 1994)126. Major virion 
components are indicated. 
 
Introduction 
 8
2.1.3. KSHV genome organization 
Members of γ herpesviruses can be further divided into γ 1 and γ 2 subgroups, based on 
sequence homology. Whereas EBV belongs to the γ 1 subgroup, KSHV, HVS, rhesus 
monkey rhadinovirus (RRV), retinofibromatosis-associated herpesvirus (RFHV), and 
mouse herpesvirus 68 (MHV-68) fall into the γ 2 subgroup. 
KSHV was initially identified by Moore and Chang32. The genome of KSHV was mapped 
with cosmid and phage genomic libraries from the BC-1 cell line111,130. BC-1 is a PEL cell 
line containing a high KSHV genome copy number and is co-infected with EBV. The 
KSHV genome has the standard features of rhadinovirus genomes. The latent KSHV 
genome appears to be in a circular conformation, while the encapsidated products of 
lytic replication are linear125. The BC-1 KSHV genome consists of a 140.5-kb-long 
unique coding region flanked by multiple G+C rich 801-bp terminal repeat sequences 
which are the presumed sites for genome circularisation86 (Fig. 3). The number of 
repeats at each end varies. Some molecules contain as few as no or 1 repeat at one 
terminus and as many as 35-45 at the other terminus; most, however, contain multiple 
repeats at each end86. During the lytic replication, the viral progeny DNA is synthesized 
by a rolling-circle mechanism125.  
The genome of KSHV contains at least 89 open reading frames (ORFs)111,130. The viral 
genome can be divided into highly conserved blocks, which are interrupted by 
interspersed regions of unique genes. The conserved genes have been marked by the 
prefix “ORF”, while the unique genes have been designated K1 to K15130. The genes 
with high conservation degree are predicted to have metabolitic and catalytic functions in 
the replication of the viral DNA and are taken together in a set of “ancient” genes 
conserved in all mammalian herpesviruses142.  
KSHV harbors numerous ORFs with homology to cellular genes which are involved in 
modulating cellular signal transduction pathways, cytokine-regulated cell growth, 
apoptosis, and cell cycle control. To achieve persistent infection, KSHV has evolved 
elaborate mechanisms that target and modulate different aspects of the host’s immune 
system.  
The KSHV genome also contains two lytic origins of DNA replication that are inverted 
duplications of each other: the left is located between K4.2 and K.5, and the right 
between K12 and ORF717,92.  
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2.1.4. Gene expression program of KSHV 
Subsequent to primary infection, herpesviruses persist life-long in the host. The gene 
expression program of KSHV can be divided into two phases: non-productive (latent) 
phase and productive (lytic) phase. The viral gene expression program can be switched 
from latent to lytic by phorbol ester and sodium butyrate. KSHV gene expression in PEL 
cells was analysed during the latent and lytic phase and the viral genes were grouped 
into 3 classes134: 
• Class I genes are expressed during the latent phase and are not induced 
by 12-O-tetradecanoylphorbol-13-acetate (TPA). The following genes 
belong to this group: ORF73 [latency-associated nuclear antigen-1 (LANA-
1)], ORF72 (viral cyclin D) and ORF K13 (v-FLIP).  
• Class II genes are primarily clustered in nonconserved regions of the 
genome and include most of the virus-encoded cytokines. These genes 
are transcribed without TPA treatment, but are further induced to higher 
transcription levels by chemical treatment. The following genes belong to 
this group: three CC family chemokines (ORF K4, ORF K4.1, ORF K6), a 
BCL-2 analog (ORF16), etc. 
• Class III genes represent ORFs that cannot be detected without TPA and 
are induced by this chemical. This class includes lytic genes which are 
transcribed during active infection and are necessary for efficient viral 
replication and virion particle production [e. g. ORF21 (thymidine kinase), 
ORF25 (major capsid protein), ORF26 (capsid protein), ORF50 (the 
replication and transcriptional activator Rta)]134. 
 
Rta (ORF50) of KSHV is able to reactivate the virus from latency in PEL cell lines59,94,152. 
Most of the KSHV - infected cells in PEL and KS clinical samples are latently infected 
with the virus and only few cells show spontaneous lytic replication31,46. 
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2.2. Viral modulation of host signalling pathways activating the SRE element 
A major emphasis of current research is to determine which genes are responsible for 
KSHV-driven tumor cell growth. Several studies on single KSHV genes have shown that 
KSHV possesses a complex molecular capacity to regulate cell proliferation by 
interfering with different cell signalling pathways. Many of these signal transduction 
pathways converge at transcription factors that bind to specific enhancer elements [e.g. 
SRE (serum response element), AP-1 (activating protein-1), etc.] found in the promoters 
of various genes and modulate the transcription of these genes. Since this study 
focuses on a viral protein which modulates a signalling pathway via SRE (see results), 
more information about this enhancer element will be given in this part of the thesis. 
 
2.2.1. Serum response element (SRE)  
The SRE binding site is a key regulatory element in the promoters of many cellular early 
response genes involved in cell growth (c-fos, FosB, JunB, Egr-1, Egr-2, IL2Rα, etc.), 
differentiation (Cyr61, Pip92), as well as muscle development and function (cardiac α- 
actin, skeletal α – actin, smooth muscle γ – actin)30. The SRE element contains two 
distinct binding sites for serum response factor (SRF) and ternary complex factor (TCF) 
(Fig. 4). Upon phosphorylation a dimer of SRF and one molecule of TCF form a ternary 
complex, which binds to the SRE element139. 
 
2.2.1.1. Serum Response Factor (SRF) 
SRF has a molecular weight of 67 kD and contains a DNA binding domain, a 
transactivation domain and several phosphorylation sites30. SRF can be activated by a 
variety of agents, including serum, lysophosphatidic acid (LPA), lypopolysaccharide 
(LPS), 12-O-tetradecanoylphorbol-13-acetate (TPA), cytokines, tumor necrosis factor-α 
(TNF-α), T-cell virus 1 activator protein, hepatitis B virus activator proteins pX, activated 
proto-oncogenes and oncogenes as well as antioxidants and UV light8,30. SRF is 
regulated by interactions with other transcription factors e.g. Sp1, ATF6 and myogenic 
regulatory factors100,146. 
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2.2.1.2. Ternary Complex Factor (TCF) 
TCFs are a subgroup of the ETS protein family, which was first described in the context 
of c-fos gene regulation138. The transcription factors ELK-1, Sap1a and Net/Erp/Sap2, 
which share a characteristic “winged helix – turn - helix” DNA – binding domain belong 
to this group17. TCFs are targets for mitogen-activated protein kinases (MAPK)138. 
Several kinases, including extracellular–signal regulated kinase (ERK), Jun N–terminal 
kinase [known as stress-activated protein kinase (SAPKs)] and other subfamilies of 
MAPK take part in the phosphorylation of TCFs30. Transcriptional activation by ELK-1 
was shown to depend on several consensus sites in the carboxy-terminal domain of 
ELK-1 that are rapidly phosphorylated following mitogen stimulation of cells and by 
MAPKs in vitro56,82,96. Although several sites are phosphorylated in vivo, Ser383 appears 
to be critical both for trans-activation and for ternary complex formation56,56,74,96,150.  
There are two general classes of signalling mechanisms involved in SRE activation, a 
TCF-dependent and a TCF-independent pathway30 (Fig. 4).  
               
Fig. 4: Diagrammatical presentation of the pathways involved in c-fos gene activation.  
Four signalling pathways leading to the activation of the c-fos promoter via the SRE element are indicated. 
The activation of SRE by the RAS-RAF-MAPK-ERK and Rac/Cdc42/GCK/MEKK1/JNK/SAPK pathways 
requires the phosphorylation of both TCF and SRF. The RhoA and Ca2+ calmodulin-dependent kinase 
(CaMK) induced activation of SRE depends only on the phosphorylation of SRF. Question marks indicate 
unknown pathways (adapted from Chai and Tarnawski, 2002)30. 
 
Extracellular stimulations such as serum, mitogens, UV, etc 
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The TCF-dependent pathway involves the RAS-RAF-MEK-ERK and 
Rac/Cdc42/GCK/MEKK1/JNK/SAPK cascades75. Both the phosphorylation of TCFs and 
the phosphorylation of SRF are required for the activation of SRE by this pathway (Fig. 
4).  
The TCF–independent pathway activated by the Rho family of GTPases or Ca2+ 
calmodulin-dependent kinase (CaMK) does not lead to the phosphorylation of TCFs 
(Fig. 4). The activation of SRE by the TCF-independent pathway requires only the 
phosphorylation of SRF. 
Recently, it was observed that during infection of HUVEC (human umbilical vein 
endothelial cells) cells KSHV activates multiple MAPK pathways including MEK1/MEK2, 
JNK and p38 (Gao et al., unpublished). Moreover, the infectivity of KSHV and the viral 
lytic replication and production of infectious virions can be reduced up to 80% in the 
presence of specific inhibitors of MAPKs (Gao et al., unpublished). This demonstrates 
that the activation of multiple MAPK pathways is essential for successful KSHV infection 
and replication. 
 
2.2.2. Viral proteins modulating host signalling pathways related to SRE  
Several viral proteins have been identified as modulators of host signalling pathways 
activating the SRE binding site. In each case the mechanism of modulation is different: 
(i) some viral proteins activate the phosphorylation of specific transcription factors 
binding to SRE, (ii) others bind directly to SRF or ELK-1, and (iii) there are viral proteins 
with a complex mechanism of activation of SRE. Several examples of viral proteins 
activating SRE are listed in the text below. 
In 1997, it was reported that the Tat protein of HIV (Human Immunodeficiency virus) 
activates the c-fos promoter via the SRE binding site55. Three years later the Tax protein 
of T-cell leukemia virus type 1 (HTLV-1) was shown to have similar properties141. Tax 
activates the expression of cellular immediate early genes controlled by the SRE 
element via direct binding to TCFs. In addition, Tax interacts with CREB binding protein 
(CBP), which is essential for Tax activation of SRF-mediated transcription141. 
The hepatitis C virus (HCV) core protein has oncogenic potential. The MAPK-ERK 
pathway and its downstream target, SRE, are activated in BALB/3T3 cells producing the 
HCV core protein50. In the presence of a mitogenic signal, the HCV core protein 
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enhances ELK-1 activation by acting downstream of MEK, however without affecting 
ERK activity and ELK-1 phosphorylation. This suggests that HCV core protein activates 
ELK-1 through a pathway alternative to the typical phosphorylation cascade50,54.  
Hepatitis delta virus (HDV) is a viroid whose replication is dependent on hepatitis B virus 
(HBV). There are only a few studies on the effects of HBV and HDV proteins [HDV 
antigens (HDAgs)] on intracellular signalling pathways. One of them reveals that HBV X 
protein (HBx), alone or with the large isoform of HDAg (LHDAg), synergistically activates 
the SRE-dependent pathway. HBx enhances the transcriptional ability of ELK-1, 
whereas LHDAg activates the transcriptional ability of SRF57. 
Finally, the VP3 protein of hepatitis A virus (HAV) has recently been added to the group 
of viral proteins activating cellular signalling pathways which induce SRE77. 
 
2.3. The Mediator complex 
The regulation of cellular gene expression requires the carefully choreographed binding 
of general transcription factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH to the 
RNA polymerase II (Pol II)65. The response to activators of transcription (e. g. Gal4, 
VP16 of HSV, the adenoviral E1A protein, etc.) requires additional factors referred to as 
coactivators. A group of these factors is involved in the regulated alteration of chromatin 
structure. One such coactivator, the Mediator, is an approximately 2 megadaltons multi-
subunit complex capable of responding to different activators95,107,119. The Mediator 
plays a key role in bridging DNA-bound activators to the general transcriptional 
machinery, especially RNA polymerase II, and the core promoter88. The subunits of the 
Mediator are necessary for a variety of positive and negative regulatory processes and 
serve as direct targets for the activators. The general requirement for individual Mediator 
subunits in global gene regulation differs. Some components are needed for the 
regulated expression of nearly all genes, whereas others are only needed for a certain 
subset of genes63,67. The exact molecular mechanism of Mediator-dependent 
transcriptional activation still remains unclear. Analyses by electron microscopy and 
image processing demonstrated striking similarities between the Mediator complexes 
isolated from yeast, mouse and human cells6. The regulation and magnitude of 
transcription is a function of the promoter architecture and the activator’s influence on 
the Mediator conformation88. In two-dimensional projections, the Mediator alone appears 
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compact but in the presence of RNA polymerase II, the Mediator is altered to an 
extended structure consisting of three domains: a tail followed by middle and head 
domains. The head and middle regions, which contain a subset of conserved Mediator 
proteins, make contact to RNA polymerase II6 (Fig. 5). The tail domain represented by 
non-conserved subunits is needed for the function of a wide variety of activators63. 
 
 
 
 
 
 
 
 
 
 
Fig. 5: The Mediator model of activator-dependent transcription.  
Shown is a hypothetical promoter containing a canonical TATA box and interacting with the 
TFIID complex. The arrow within the TFIID complex represents the start site of transcription. 
The activator is shown binding to its DNA sites and recruiting the Mediator to the promoter via a 
physical interaction with a Mediator module (indicated by the overlap between the activator and 
the respective Mediator module). The head, middle and tail domains of the Mediator are 
indicated (adapted from Lewis and Reinberg, 2003)88. 
 
 
2.3.1. Viral proteins directly interacting with subunits of the Mediator complex 
 
2.3.1.1. Human activator-recruited cofactor (ARC92/ACID1) and VP16 
ARC92/ACID1 is a subunit of the Mediator. The structure of ARC92/ACID1 gene is of 
ancient origin and is conserved in mammals and higher eukaryotes. Using an affinity 
purification procedure ARC92/ACID1 was identified as a novel specific target of the 
herpes simplex transactivator VP16102. This interaction serves as an important 
transducer of transcription activating signals from the VP16 activation domain to the 
RNA polymerase II transcriptional machinery. Depletion of the ARC92/ACID1 - Mediator 
(A-Med) complex from HeLa nuclear extracts abolishes activation by VP16102. The 
Mediator-binding module of ARC92/ACID1 is a von Willebrand factor type A (VWA) 
domain which possesses the typical features of a protein-protein interaction module. It 
RNA Pol II
tail
Mediator
middle
head
DNA
TATA TFIID
Activator 
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consists of a rigid scaffold composed of helices grouped around a core that is formed 
from β-sheets102. The VP16 binding region is the ACID (activator interaction domain) 
domain which is still poorly characterized (see Fig. 6). The overexpressed N-terminal 
290 amino acids of ARC92/ACID-1 (including the VWA domain), called NTD have a 
strong dominant-negative effect on the VP16 activation in mammalian cells102.  
 
 
 
 
 
 
Fig. 6: Schematic representation of ARC92/ACID1.  
The von Willebrand factor type A (VWA) domain and the VP16 binding domain are 
indicated102. 
 
 
2.3.1.2. Suppressor of RAS protein (Sur-2) and E1A 
The Mediator subunit Sur-2 was originally discovered in the vulval signalling pathway of 
the nematode Caenorhaditis elegans143. Sur-2 acts downstream of the RAF/MAP kinase 
pathway. A null Sur-2 mutation gives rise to pleiotropic phenotypes, including partial 
larval lethality and sterile adults143. The human homologue of Sur-2 is a binding target of 
the adenoviral E1A transcriptional activator and interacts with the MAPK-modified form 
of the transcription factor ELK-115. A knockout of murine Sur-2 in embryonic stem cells 
specifically prevents gene activation by ELK-1, but not by multiple other factors149. The 
activation of immediate early genes (c-fos, egr-1, etc.) in response to the RTK-RAS-
RAF-MEK-ERK pathway is defective in sur2-/- cells because ELK-1 must interact with the 
Sur-2 Mediator subunit to activate transcription149.  
 
2.3.1.3. CDK8/cyclin C and ORF A 
The ORF A protein of Walley dermal sarcoma virus (WDSV) also belongs to the list of 
viral proteins interacting with subunits of the Mediator complex. It was reported that the 
ORF A protein co-immunoprecipitates with CDK8 (cyclin-dependent kinase 8) and cyclin 
C, which form part of the Mediator complex129. 
VWA ACIDN C
1 17 226 389 543 754
Med VP16
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2.4. Different strategies to generate herpesvirus mutants 
Traditionally, biological functions of herpesviruses have been examined by using viral 
mutants. Recombinant viruses can be generated by different methods. In the past 
chemical mutagenesis was one classical genetic approach used for the generation of 
temperature-sensitive (ts) virus mutants135. Using mutagenic chemicals mutants with 
random point mutations were generated and screened for interesting phenotypes. The 
disadvantage of this technique is the difficulty to precisely identify the mutation 
responsible for an observed phenotype and to exclude second-site mutations. Another 
method that was developed in the early 1980s for herpes simplex virus is based on site-
directed mutagenesis by homologous recombination103. Using this method the desired 
mutation is introduced into the viral genome together with a selectable marker using the 
recombination and repair machinery of the cell. This technique also has the 
disadvantage that enriching and purifying mutants which have restricted growth capacity 
in comparison to the wild-type is difficult and can only be achieved with complementing 
cell lines that provide the essential gene product40,41. Another approach is to clone the 
entire genome of the virus as sets of five or more overlapping cosmid clones, which 
allows the manipulation of a cloned segment with the tools of molecular biology128. 
Similar to the above-mentioned techniques, the cosmid technology has several 
disadvantages: recombinant viruses are genetically unstable, it is difficult to identify 
suitable restriction site in large cosmids, etc. In the last few years new vehicles have 
been developed as tools for mammalian genetics such as yeast artificial chromosomes 
(YACs), PACs (P1-derived artificial chromosome) based on the origin of replication (ori) 
of bacteriophage P1, and BACs (bacterial artificial chromosome) based on the bacterial 
F plasmids72,140,148. These cloning vectors can accept foreign DNA sequences of up to 
300 kbp while remaining remarkably stable140. The first herpesvirus genome cloned as 
an infectious BAC was mouse cytomegalovirus (CMV) followed by other viruses such as 
EBV, HSV, pseudorabies virus, human CMV and KSHV112,38,39,69,131,144,147. The 
mechanisms of recombination in Escherichia coli are well studied and easily controlled 
and their application is less time consuming than recombination procedures in 
mammalian cells18. However, the presence of repetitive sequences in herpesvirus 
genomes have raised doubts about the stability of herpesvirus BACs18.  
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In comparison to members of β−herpesvirinae (hCMV, mCMV), the genetic analysis of 
KSHV, which belongs to the γ-herpesvirinae, has been hampered by severe difficulties 
in producing infectious viral particles and modifying the viral genome. The lack of a 
cellular model for efficient KSHV infection has impeded the understanding of KSHV-
related pathogenesis. Many basic questions concerning KSHV remain open. The 
primary target cell of KSHV infection in vivo as well as the function of more than 50% of 
the viral proteins is still unknown. The role of proteins controlling the activation and 
completion of the viral lytic cycle is also only partly understood39. KSHV was cultured by 
using cell lines established directly from primary effusion lymphoma or peripheral blood 
mononuclear cells of PEL patients5,21,23,29,43,52. KSHV can infect different cell types, 
including a variety of human cell types (B, T, endothelial, epithelial, fibroblast, 
keratinocyte cells) and non-human cell types (owl monkey kidney and baby hamster 
kidney fibroblast cells)26,34,48,81,101,106,114 but the primary KSHV infection rates in these 
systems remain very low (< 10%)124. Cloning KSHV as a BAC was first performed by the 
group of Hammerschmidt39. The primary rate of infection with this BAC clone was below 
1% and the reconstitution of viral mutants was inefficient39. Creating KSHV mutants for 
genome-wide screening is of little value using the above mentioned KSHV BAC clone. 
So far, the BAC technology has not been very powerful for the manipulation of KSHV. 
Therefore new alternatives must be developed for better and efficient wide screening of 
the KSHV genome. 
 
 
2.5. Objectives 
The function of a majority of KSHV proteins is currently unknown, or is only predicted 
due to sequence homology. Although many viral genes show homology to cellular genes 
and share structural similarity, their functional properties may differ from those of their 
cellular counterparts. The objective of this project was the establishment of an efficient 
screening system to identify and characterize new functions of KSHV proteins. In order 
to reach this goal, the following aims were defined:  
• the generation of a KSHV array containing all herpesviral ORFs in an 
eukaryotic expression vector by recombinatorial cloning, 
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• the screening for viral proteins modulating the SRE and AP-1 related 
signalling pathways, and 
• the analysis of the mechanism driving the observed modulation. 
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3. Results 
 
The result section is divided into two parts. The first part describes the generation of an 
expression array containing all KSHV open reading frames (ORFs) by recombinatorial 
cloning and the screening of the array for viral proteins modulating signal pathways 
dependent on SRE and AP-1 binding sites. The second part focuses on the mechanism 
driving the observed modulation.  
 
3.1. Identification of LANA-1 as an activator of SRE 
 
3.1.1. Generation of a KSHV expression array by recombinatorial cloning 
The generation of KSHV arrays in a variety of different expression vectors provides the 
possibility to perform genome-wide screens for viral-host and viral-viral protein 
interactions, localization, induction of signalling pathways, etc. Viruses, but especially 
herpesviruses, offer an interesting genome size for such projects, because their limited 
number of genes allows to study several aspects of the herpesvirus biology 
simultaneously by different methods.  
In order to generate the KSHV array in different expression vectors, the advantages of 
recombinatorial cloning (GATEWAY cloning technology), which facilitates the cloning of 
large numbers of DNA fragments by restriction endonucleases and ligase, were used. 
Recombinatorial cloning is based on site-specific recombination reactions of the λ 
bacteriophage in E. coli during lysogenization. Proteins encoded by λ phage and E. coli 
mediate the integrative and excisive recombination reactions of λ phage. These 
recombination reactions, performed in vitro, are the basis of the GATEWAY cloning 
technology. The BP reaction is a recombination reaction between a PCR product 
containing terminal attB sites and a donor vector mediated by a BP clonase mix of 
recombination proteins (Fig. 7a). The BP reaction results in the generation of an entry 
clone. The LR reaction is a recombination reaction between an entry clone and a 
destination vector, mediated by LR clonase. The attB (attL) sites are specifically 
recognized by the recombination proteins that constitute the clonase enzyme mix 
cocktails. These proteins cut to the left and to the right of the gene in the entry clone and 
ligate it into the destination vector, creating a new expression clone (Fig. 7b). There is a 
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counterselection against destination vectors without the gene of interest since they carry 
the ccdB gene, which is lethal to most E. coli strains. Thus, selection for ampicillin 
resistance chooses for E. coli cells that carry the desired product, which usually 
comprise 70-90% of the colonies. Once a DNA segment is cloned in the entry vector, it 
can easily be transferred into a destination vector (via the LR reaction) to generate an 
expression clone.  
 
                      
 
Fig. 7: GATEWAY cloning reactions. 
(a) The BP reaction. The BP reaction can transfer a PCR gene flanked by the attB sites into a 
donor vector to yield an entry vector. Only plasmids without the ccdB gene that are also 
kanamycin resistant (KnR) will yield colonies. (b) The LR reaction. An entry vector, containing a 
gene flanked by recombination sites, recombines with a destination vector to yield an 
expression vector and a by-product plasmid. The result is that a gene sequence in the entry 
vector is transferred into an expression vector, donated by the destination vector. Only plasmids 
without the ccdB gene that are also ampicillin (ApR) resistant will yield colonies. 
 
a 
b 
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PCR products flanked by the attB sites for recombination were generated of all KSHV 
ORFs and cloned into the entry vector pDONR207 by BP clonase (Uetz et al. 
unpublished). 114 DNA fragments representing full-length or partial viral genes from the 
KSHV genome were cloned into the entry vector. Subsequently, all ORFs of KSHV were 
subcloned into three different destination vectors: the yeast two-hybrid (Y2H) plasmids 
pGADT7 (ampicillin resistance) and pGBKT7 (kanamycin resistance), which were used 
to screen for viral protein-protein interactions in the yeast-two hybrid system and the 
eukaryotic expression vector pDEST-script. The rationale was to obtain a viral array, 
which can be expressed in mammalian cells and can be screened for the modulation of 
signalling pathways. The pDEST-script plasmid was generated by insertion of a cassette 
containing the two recombination sites, attR1 and attR2, flanking a chloramphenicol 
resistance (CmR) gene and a ccdB gene, into the unique EcoRV site of the pCMV-script 
vector (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Scheme of the pDEST-script vector and the recombinatorial cassette.  
Blunt-end B cassette was inserted into the EcoRV unique site in the MCS (multiple cloning site) of 
pCMV-script converting it into a destination vector. The B-cassette contains an attR1 site at the 5'-
end followed by the chloramphenicol resistance gene (Cmr) and ccdB gene. The attR2 site is at the 
3'- end of the cassette.  
 
 
 
 
EcoRV EcoRV 
EcoRV 
pCMV-script 
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For each of the generated expression constructs three E. coli colonies were picked up 
from the selection agar plates, the plasmid DNA was isolated and analysed by several 
restriction digests using different endonucleases. The efficiency of the recombinatorial 
cloning of the KSHV ORFs into different destination vectors is illustrated in Fig. 9. 
Approximately 85-95% of the analysed bacterial colonies carried the desired gene 
product. 
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Fig. 9: Restriction digest of different destination vectors by endonucleases.  
Three different bacterial colonies from each selection agar plate were analysed for the presence of 
the cloned gene of interest. DNA preparations were carried out and a restriction digest by several 
endonucleases was performed. The yeast expression vectors pGADT7 and pGBKT7 were digested 
by EcoRI and BamHI restriction enzymes (panel a). The eukaryotic expression plasmid pDEST-script 
was cut by EcoRI and HindIII restriction enzymes (panel b). Most of the E. coli clones carried the 
desired viral product (52/54=96%). Only the plasmid DNA samples with number 7 from panel a and 
number 14 from panel b showed a wrong pattern of DNA fragments after the restriction digest. M 
indicates the 1 kb DNA marker loaded on the agarose gel. 
 
 
b 
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The correct DNA sequence of the generated KSHV ORFs cloned into the entry vector 
was evaluated by sequence analyses. To test that the viral genes are properly 
expressed by pDEST-script immunofluorescence (data not shown) and Western blot 
analyses (Fig. 10) were carried out. The correct reading frame of the cloned KSHV 
ORFs was also evaluated by cloning of the gene for green fluorescence protein (GFP) 
into pDEST-script.  
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Fig. 10: Western blot analysis for the expression of KSHV ORF25 from pDEST-script.  
HEK 293 cells were transfected by pDEST-ORF25 and the lysate was stained by an antibody specific 
for ORF25 (KS 330A). As a negative control, a lysate from HEK 293 cells transfected with the empty 
pDEST-script was included. A lysate of HEK 293 cells stably transfected with the KSHV-BAC and 
stimulated with TPA was used as a positive control. 
 
 
3.1.2. Screening of the KSHV expression array for viral proteins activating SRE 
and AP-1 
SRE and AP-1 binding sites are enhancer elements present in many promoters of genes 
related to cell growth, differentiation, development and transformation. SRE is present in 
the promoters of proto-oncogenes such as c-fos, FosB and JunB87,115,156. The dimeric 
AP-1 transcription factor is composed of members of the Jun, Fos, and activating 
transcription factor (ATF) families, and the constituents of this complex may govern cell 
proliferation and related responses83.  
The activation of a signal transduction pathway by a single viral protein can be 
monitored by the expression level of the luciferase reporter gene controlled by a 
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promoter containing these enhancer elements. Therefore, the KSHV expression array 
was screened for viral genes acting on signalling pathways which lead to an activation of 
SRE or AP-1 by luciferase reporter assays. 
Individual viral ORFs were cotransfected into HEK 293 cells together with a luciferase 
reporter plasmid containing five copies of the SRE element derived from the promoter of 
the c-fos proto-oncogene or five copies of an AP-1 binding site (Fig. 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Schematic representation of the screening in HEK 293 cells. 
Test of the KSHV expression array for the induction of signalling pathways activating SRE and AP-1. 
Individual viral ORFs were cotransfected into HEK 293 cells together with a luciferase reporter 
plasmid containing five copies of the SRE element derived from the promoter of the c-fos proto-
oncogene or five copies of an AP-1 binding site. 48h after transfection the cells were lysed and the 
luciferase activity was measured. 
 
 
The empty pDEST-script vector was used as a negative control. The dominant positive 
RAS V12, which is a constitutively active mutant of RAS, was included as a positive 
control. Two days after transfection the cells were lysed and the luciferase activity was 
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measured (Fig. 12). The transactivation of the luciferase reporter constructs by each 
viral protein is indicated as fold activation compared to the negative control. 
One viral protein, LANA-1 (ORF73), was identified as a strong activator of SRE. LANA-1 
activated SRE approximately 16- and 20-fold above background (Fig. 12a). Several viral 
proteins induced a low level activation (2- to 4-fold) of SRE, which was considered to be 
either unspecific or of minor importance (Fig. 12a). In the screening for signal 
transduction pathways inducing AP-1, no viral gene activating the luciferase reporter 
construct more than 2- to 3-fold above background was detected (Fig. 12b).  
 
 
Fig. 12: LANA-1 is an activator of the serum response element (SRE).  
LANA-1 was identified as an activator of the SRE element. The KSHV expression array consisting of 
all viral ORFs cloned into an eukaryotic expression vector was screened in HEK 293 cells using a 
luciferase plasmid with 5 SRE binding sites (a) and luciferase plasmid containing 5 AP-1 binding 
sites (b). 
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This observation differs from the data presented by An et al. on LANA-1 - mediated IL-6 
promoter activation via AP-13. The different results are probably caused by the fact that 
An and colleagues used a luciferase plasmid containing 6 different AP-1 binding sites 
(TGAGTCAG TGAGTCAC TGACTCAC TGACTCA TGAGTCAGC TGACTC) in the 
promoter, in comparison to the AP-1 binding site (7x TGACTAA) present in the plasmid 
used in this study or, alternatively, by differences in the vector backbones used.  
 
3.2. Mechanism of LANA-1-induced SRE activation 
In the current study, the mechanism of LANA-1-mediated activation of the SRE binding 
site was explored considering the following possible mechanisms: 
• LANA-1 functions as a transcription factor that directly binds to the SRE 
binding site and activates transcription.  
• LANA-1 induces a signal transduction pathway that leads to activation of 
transcription factors binding to the SRE element. 
• LANA-1 acts as a transcriptional coactivator of a SRE family member by 
directly binding to SRF or TCFs. 
• LANA-1 directly modulates the basal transcription machinery by interfering 
with some of its subunits. 
 
3.2.1. Specificity of the LANA-1 effect on SRE  
To examine the specificity of SRE activation by LANA-1 increasing amounts of the 
LANA-1 plasmid (50 to 250 ng per well) were cotransfected with 50 ng of the luciferase 
reporter vector. Three independent experiments showed a dose-dependent effect of 
LANA-1 on SRE (Fig. 13a). With 50 ng of the LANA-1 plasmid the SRE activity was 
increased 5-fold. With increasing concentrations of the LANA-1 plasmid the effect was 
stronger and with 250 ng of LANA-1 plasmid DNA an induction between 20- and 25-fold 
was detected. To correct for variations in transfection efficiency, the Renilla luciferase 
encoding plasmid pRL-TK was used as a normalization control. 
To ensure that the effect seen was not due to sequences present in the backbone of the 
plasmid used, LANA-1 vectors with different backbone were tested for SRE activation. A 
similar effect was observed with every construct indicating that LANA-1 and not the 
vector induced SRE (data not shown).  
Results 
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Similar results were obtained in HeLa cells, but neither in DG75 B-cells nor Jurkat T 
lymphocytes, suggesting that a cell-type specific cofactor present in epithelial/endothelial 
but missing in lymphocytes is mandatory for stimulation (data not shown). 
Previously, it was reported that LANA-1 is a transcriptional modulator of a variety of viral 
and cellular promoters including EBV Cp, LANA-1, HIV-1 LTR (in some cell lines), 
telomerase reverse transcriptase and promoters containing SP1 and CAAT binding 
sites123. Thus, the effect of LANA-1 on a variety of promoters was compared. Several 
vectors expressing the firefly luciferase gene controlled by synthetic promoters 
containing a basic TATA element and various binding sites for AP-1, NF-kB, SRE and 
ISRE were evaluated in cotransfection experiments with an expression vector for LANA-
1 (Fig. 13b). A luciferase reporter vector with the HIV-1 LTR was also included. It was 
found that LANA-1 strongly activated another promoter besides SRE which contained 5 
interferon-stimulated response elements (ISRE). Several other promoters containing AP-
1 or NF-κB binding sites or the HIV-1 LTR, on the other hand, were not activated but 
repressed, indicating that LANA-1 is a promiscous, but still selective transcriptional 
modulator. 
The activation of ISRE by LANA-1 which was as strong as the induction by 500 units/ml 
of IFN α indicated a possible role of LANA-1 in IFN type I-dependent signalling 
pathways. The functional relevance of stimulation of type I interferon signalling by LANA-
1 is currently unknown and is an object of investigation in another study in our 
laboratory. 
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Fig. 13: Specificity of the LANA-1 - related activation of SRE. 
(a) Dose-dependent effect of LANA-1 on SRE. Increasing amounts of LANA-1 plasmid DNA were 
cotransfected with the SRE luciferase plasmid. (b) LANA-1 transactivation of cellular promoters is 
specific but promiscous. An expression vector for LANA-1 was cotransfected into HEK 293 cells 
with a variety of luciferase reporter plasmids containing AP-1, NF-kB, SRE, ISRE binding sites or 
the HIV-1 LTR. As negative controls, cells cotransfected with the empty pCR3 vector were 
included. The positive controls were cells cotransfected with plasmids expressing either RAS V12 
or HIV-1 Tat, or stimulated with either IFN α or with phorbol ester (TPA) and ionomycin (iono). 
Data are representative of three independent experiments, and error bars represent standard 
error values. To correct for variations in transfection efficiency, the Renilla luciferase encoding 
plasmid pRL-TK was used as a normalization control.  
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3.2.2. LANA-1 is not a general processivity factor 
Subsequently, it was evaluated whether LANA-1 would stimulate activated promoters 
independently of the transcription factor binding site. A similar set of luciferase reporter 
vectors as in Fig. 13 was used and stimulated with the respective positive controls in the 
absence or the presence of LANA-1 (Fig. 14). As a negative control HEK 293 cells were 
cotransfected with the empty pDEST-script plasmid. 48 h post transfection the cells 
were harvested and the luciferase activity was measured. To correct for variations in 
transfection efficiency, the Renilla luciferase encoding plasmid pRL-TK was used as a 
normalization control. LANA-1 was suppressive for the promoter containing AP-1 binding 
sites and for the IL-6 promoter, but had no or slight suppressive effect on the promoter 
containing NF-κB binding sites (see discussion). Moreover, LANA-1 further increased 
the activity of stimulated SRE and ISRE promoters (Fig. 2b), suggesting (i) that it only 
acts on specific promoters and (ii) that LANA-1 probably has a different mode of action 
as the transcription factors themselves (Fig. 14). 
 
 
Fig. 14: LANA-1 is not a general processivity factor. 
HEK 293 cells transfected with AP-1, NF-kB, SRE, ISRE and IL-6 promoter luciferase reporter 
plasmids were either cotransfected with the positive control plasmid RAS V12 or stimulated with 
either IFN α or phorbol ester (TPA) and ionomycin (iono). Additionally, LANA-1 was transfected to 
evaluate whether it is a general processivity factor or specific for SRE and ISRE. 
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In order to assess if LANA-1 directly binds to DNA, an electromobility shift assay was 
carried out. The experiment did not demonstrate a direct binding of LANA-1 to SRE 
(data not shown). Other possible mechanisms of action of LANA-1 were therefore 
investigated.  
 
3.2.3. The role of the MEK/ERK-1/2 MAP kinase pathway in LANA-1-mediated 
activation of SRE 
Several reports demonstrated that KSHV also affects cell cycle regulation through 
mitogenic pathways9,22,104,108,117. The activation of promoters containing SRE binding 
sites occurs via different pathways (see introduction). RAS-induced activation of SRE is 
mediated by a sequential phosphorylation of RAF, MEK-1/2, ERK-1/2 and the ternary 
complex factor ELK-1 (Fig. 15a). In order to investigate whether the MEK-ERK pathway 
plays a role in the activation of SRE by LANA-1 the following experiments were carried 
out. The effect of LANA-1 on SRE was evaluated in the presence and absence of 
MEK1/2 inhibitors. Two different chemicals were used, PD98059 and U0126. PD98059 
inhibits the phosphorylation activation of MEK1 by upstream kinases. U0126 is a specific 
inhibitor of the phosphorylation activation of MEK1 and MEK2 by upstream kinases. The 
SRE luciferase reporter vector was cotransfected with empty pCR3, LANA-1 and RAS 
V12, respectively, and the specific MEK1/2 inhibitors were added 24 h later (Fig. 15b). 
The luciferase activity was determined 40 h post transfection. The two MEK-1/2 
inhibitors U0126 and PD98059 inhibited the activation of SRE by LANA-1 to a similar 
extent as they reduced the induction of SRE by RAS V12 (Fig. 15b). This observation 
indicated that the phosphorylation of MEK1/2 kinases might be necessary for the 
activation of SRE by LANA-1.  
In addition to the luciferase assays, a Western blot experiment with anti-phospho-
MEK1/2 antibody was performed to assess the effect of MEK1/2 inhibitors. An increased 
phosphorylation of MEK-1/2 by LANA-1 (Fig. 15c, line 3) and a very strong band for RAS 
V12 induced phosphorylation of MEK1/2 was detected, as was expected. The specific 
inhibitor PD98059 reduced both the RAS V12-, as well as the LANA-1-induced MEK1/2 
phosphorylation (Fig. 15, lines 2, 4 and 6). 
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Fig. 15: LANA-1 induces the MEK/ERK-1/2 MAP kinase pathway. 
(a) Scheme of the RAS induced activation of SRE binding site. (b) Inhibition of LANA-1-induced SRE induction 
by inhibitors of MEK-1/2 phosphorylation. HEK 293 cells were transfected with pSRE-luc and RAS V12 in the 
presence or absence of U0126 or PD98059 MEK-1/2 inhibitors. (c) LANA-1 induces the phosphorylation of 
MEK-1/2 as shown by Western blot analysis using a mAB specific for phosphorylated MEK-1/2 (α P* MEK1/2) 
and an α MEK1/2 antibody recognizing all forms of MEK1/2.  
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These experiments revealed that the phosphorylation of MEK1/2 might play an important 
role in the LANA-1-mediated activation of SRE. 
 
3.2.4. LANA-1 induces the phosphorylation of the ternary complex factor ELK-1 
In the RAS-induced MAPK cascade the phosphorylated MEK1/2 kinases subsequently 
activate ERK1/2 (Fig. 15a). ERK1/2 mediate the phosphorylation of the ternary complex 
factor ELK-1 on Ser383 (see introduction). Thus, it was investigated if the 
phosphorylation of ELK-1 on Ser383 is enhanced in the presence of LANA-1. A p42/44 
in vitro MAP kinase assay was performed using lysates of HEK 293 cells transfected 
either with LANA-1, RAS V12 or the empty pCR3 vector. Active phosphorylated ERK-1/2 
was selectively precipitated using an immobilized antibody, the precipitates were 
incubated with ELK-1 fusion protein and ATP and subsequently the ELK-1 
phosphorylation at Ser383 was analysed by Western blot using an anti-phospho ELK-1 
specific antibody. An approximately 3-fold enhanced ELK-1 phosphorylation on Ser383 
in the lysates of cells transfected with LANA-1 was detected (Fig. 16a, lane 2), which 
was even more enhanced than in cells transfected with the two positive controls ERK-2 
and RAS V12 (Fig. 16b, lanes 3 and 4).  
Fig. 16: LANA-1 induces a phosphorylation of the ternary complex factor ELK-1. 
(a) LANA-1-induced increased ERK-1/2 activity indicated by an in vitro kinase assay. Cells transfected 
with pCR3, ERK-2, RAS V12 or LANA-1 were lysed and analysed for ERK-1/2 activity in an in vitro 
kinase assay using a mAB specific for phosphorylated ELK-1 (α P* ELK-1). (b) Quantitative analysis 
of the LANA-1-induced ELK-1 phosphorylation. The x-ray film shown in (a) was scanned and analysed 
by the quantification software Quantity One.  
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3.2.5. LANA-1 acts through both SRF and TCF binding sites  
In order to determine whether the SRF or TCF binding sites are required for the 
induction of the SRE element in response to LANA-1, HEK 293 cells were transiently 
transfected with the wild-type or mutated SRE-luciferase plasmids (Fig. 17a). Each 
reporter plasmid contained a single copy of the wild-type or mutated SRE element. As a 
positive control dominant positive RAS V12 and as a negative control the empty pCR3 
vector were used. The RAS V12-induced SRE activation can be mediated by TCF-
dependent or independent pathways, both of which require SRF (see introduction). As 
expected, dominant positive RAS V12 was still able to activate the promoter containing 
the mutated TCF binding site, but not the one with the mutated SRF binding site (Fig. 
17b). LANA-1, however, showed a completely different picture. Mutation of either the 
SRF or TCF binding site did not block the ability of LANA-1 to activate the promoter and 
LANA-1 was still able to induce both mutant promoters to approximately 50% of the level 
of the wild-type SRE promoter activated by LANA-1 (Fig. 17b), suggesting that LANA-1 
either modulates both TCF and SRF pathways or acts downstream of these two 
transcription factors. 
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Fig. 17: LANA-1 acts through both SRF and TCF binding sites.  
(a) Schematic representation of the luciferase reporter constructs used in the transfection assay: 
wtSRE-luc with wild-type SRE binding site from the c-fos promoter, mSRF-luc with mutated SRF 
binding site and mTCF-luc with mutated TCF binding site. (b) LANA-1 acts via both SRF and TCF 
binding sites in the SRE element. HEK 293 cells were transiently transfected with luciferase reporter 
constructs containing either the wild-type SRE binding site from the c-fos promoter or SRE sites 
deficient for SRF and TCF binding. 
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3.2.6. LANA-1 interacts with the specific transcription factor SRF  
Next, the cellular counterparts of LANA-1 in the activation of the SRE inducing signalling 
pathway were investigated. First, it was tested whether LANA-1 interacts directly with 
some of the specific transcription factors. To assess whether SRF and LANA-1 interact, 
a co-immunoprecipitation was carried out using a lysate from HEK 293 cells that were 
transiently transfected with LANA-1. As a negative control, cells transfected with the 
empty pCR3 vector were used. In these cells LANA-1 was coprecipitated with 
endogenous SRF (Fig. 18a). Subsequently it was tested whether the transcriotion 
factors ELK-1, STAT-1 or SpiB would interact with LANA-1. 
ELK-1, STAT-1 and SpiB were cloned by recombinatorial cloning into the pDONR207 
vector and subsequently into the expression vector pGBKT7. LANA-1 was similarly 
subcloned into the pGADT7 vector. Proteins expressed from these plasmids are tagged 
either with c-Myc (pGBKT7) or hemagglutinin (HA) (pGADT7 vector) epitopes. The 
expression of the cloned genes in these two plasmids is driven by a T7 promoter, which 
can be activated by a simultaneous infection with a recombinant vaccinia virus 
expressing the T7 RNA polymerase (Fig. 18b).  
To assess the interaction between LANA-1 and ELK-1, STAT-1, and SpiB, HEK 293 
cells were first infected by recombinant vaccinia virus expressing T7 RNA polymerase 
and subsequently cotransfected with LANA-1 and the vector expressing the respective 
transcription factor. 48 h post transfection the cells were lysed and the overexpressed 
Myc-tagged transcription factors and HA-tagged LANA-1 were immunoprecipitated 
either with anti-HA (lanes 1-4) or anti-Myc (lanes 5-8) antibodies as indicated in Fig. 18c. 
After SDS-PAGE electrophoresis, a Western blot was carried out with anti-c-Myc and 
anti-HA antibodies (Fig. 18c, on the right). As a control for each experiment lysates from 
HEK 293 cells transfected only with single expression vectors were included (Fig. 18c, 
lanes 2, 3, 6 and 7). As an additional control a lysate of HEK 293 cells infected with 
vaccinia virus only was used (Fig. 18c, lanes 1 and 5). In summary, these co-
immunoprecipitation assays indicated that LANA-1 binds directly to SRF transcription 
factor (Fig. 18a), but not to ELK-1, STAT-1 and SpiB (Fig. 18c). 
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Fig. 18: LANA-1 interacts with SRF.  
(a) LANA-1 interacts with the transcription factor SRF as shown by CoIP. Endogenous SRF was 
precipitated from lysates of HEK 293 cells transiently transfected with LANA-1. (b) Schematic 
representation how the experiment shown in (c) was performed. (c) LANA-1 does not interact 
with SpiB, ELK-1 or STAT-1 in CoIP experiments. HEK 293 cells were infected with recombinant 
vaccinia virus expressing T7 RNA polymerase and subsequently cotransfected with LANA-1 and 
the vector expressing the respective transcription factor, as indicated. The proteins were 
precipitated and detected in Western blot with anti-HA and anti-myc antibodies. TF indicates 
whether the transcription factors SpiB, ELK-1 or STAT-1 were transfected or not. 
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3.2.7. LANA-1 acts through the Mediator complex 
Since Lana-1 has a pleitropic effect on several promoters and since LANA-1-induced 
SRE activation was only partially blocked by either of the two mutations in the SRF and 
TCF binding sites (Fig. 17b), we hypothesized that LANA-1 acts downstream of the SRE 
binding site and has a more direct effect on the transcriptional activation. Transcriptional 
activation by the herpesviral VP16 protein requires the Mediator subunit ARC92/ACID-1 
(MED 25)14,102 which also participates in the activation of type I-interferon inducible 
promoters (Meisterernst et al. unpublished). We thus speculated that the Mediator is 
involved in LANA-1-induced transcriptional activation as well. The Mediator complex 
serves as a “bridge” for transferring positive as well as negative signals from different 
activators or inhibitors (specific transcription factors) to the polymerase. 
To investigate if the effect of LANA-1 on SRE is the result of a direct interaction with 
Mediator proteins a variety of co-immunoprecipitation assays were carried out. In fact, it 
was found that LANA-1 interacts with the Mediator complex. In co-immunoprecipitation 
(CoIP) experiments the overexpressed LANA-1 protein was precipitated with several 
different Mediator subunits including PCQAP (MED 15), ARC92/ACID-1 and Sur-2 (Fig. 
19a-c). Both LANA-1 and GFP-tagged LANA-1 coprecipitated with the endogenously 
expressed Mediator subunit PCQAP (Fig. 19a). As a negative control, a lysate from HEK 
293 cells transfected with the empty pCMV-script vector was included (Fig. 19a, lines 1 
and 4). LANA-1 was also coprecipitated with overexpressed (Fig. 19b, lanes 5-8) as well 
as endogenous ARC92/ACID1 (lanes 1-4).  
VP-16 can control transcriptional activation in mammalian cells by direct binding to the 
ARC92/ACID-1 protein of the Mediator complex102. The NTD domain of ARC92/ACID1 
has a dominant negative effect on the activation by VP16102 (see introduction). When 
overexpressed in mammalian cells NTD replaces the endogenous ARC92/ACID-1 and 
blocks the transcriptional activation by VP-16. To evaluate if the mechanism of binding 
of LANA-1 to the ARC92/ACID-1 protein is similar as for the HSV-1 transactivator VP16, 
luciferase assays were carried out, in which the SRE or ISRE reporter constructs were 
cotransfected together with LANA-1 in the absence or the presence of the 
overexpressed dominant negative NTD domain of ARC92/ACID-1. As a positive control 
for the NTD domain, the pGLMRG5 plasmid containing Gal4 binding sites and Gal4 
fusion proteins of full length VP16 and the VP16 H1 domain were used (Fig. 20a and b).  
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Fig. 19: LANA-1 interacts with the Mediator.  
(a) LANA-1 interacts with the Mediator protein PCQAP as shown by CoIP. Lysates of HEK 293 cells 
transiently transfected with LANA-1 were either precipitated with the anti-LANA-1 mAB or an anti-PCQAP 
mAB. The Western blot analyses were carried out with either of the two antibodies or an antibody against 
the Med7 Mediator protein. Lines 2 and 5 refer to the lysates from cells expressing wild-type LANA-1 
used in the CoIP. Lines 3 and 6 refer to the lysates from cells expressing GFP-tagged LANA-1. (b) 
LANA-1 interacts with the Mediator protein ARC92/ACID1 as demonstrated by CoIP. (c) LANA-1 
interacts with the Mediator protein Sur-2 as shown by CoIP.  
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Fig. 20: Dominant negative effect of NTD on LANA-1 activation. 
(a) Model for NTD–related inhibition of transcriptional activation by VP16. (b) The LANA-1-
mediated activation of SRE and ISRE is abrogated by the N-terminal domain (NTD) of 
ARC92/ACID1. HEK 293 cells were transfected with pSRE-luc, pISRE-luc or pGLMRG5 luciferase 
plasmids and LANA-1, dominant positive RAS V12, full-length VP16 or the H1 domain of VP16. 
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The LANA-1-induced activation of both SRE and ISRE was inhibited by NTD similar to 
the VP16 control. NTD lead to a 84% inhibition of LANA-1-induced SRE activation and 
to a 85% inhibition of LANA-1-induced ISRE activation. In a parallel experiment, different 
amounts of the NTD expression vector were evaluated. A dose-dependent effect of NTD 
was observed, in that increasing concentrations of NTD led to stronger inhibition of the 
LANA-1-induced SRE and ISRE activation (data not shown). 
To prove that the inhibition by NTD is specific for the viral transactivators VP16 and 
LANA-1, additional experiments were performed. RAS V12 was cotransfected with SRE 
reporter vector in presence or absence of NTD. The same was done for ISRE reporter 
vector activated by IFN α. Intriguingly, NTD had no effect on SRE activation by RAS V12 
and ISRE activation by exogenous IFN α (Fig. 20b), suggesting that here ARC92/ACID-
1 is not involved as a Mediator subunit (see discussion). As expected, NTD also had no 
effect on v-FLIP-induced activation of a NF-kB luciferase construct98, indicating that the 
observed effect is specific to LANA-1 but not to other KSHV proteins (data not shown).  
 
3.2.8. The N-terminal domain of LANA-1 binds to the Mediator subunit 
ARC92/ACID1 
To identify the domains within LANA-1 which bind to the Mediator a variety of His- and 
GST-tagged mutants of LANA-1 were used in CoIPs and GST pull-down assays. The C-
terminal deletion mutants of LANA-1 used in the CoIP experiments are illustrated in Fig. 
21a. The CoIPs were carried out using lysates of HEK 293 cells transfected with N-
terminally His-tagged wild-type LANA-1, L25, or L26. As a negative control, HEK 293 
cells were transfected with the empty pCR3 vector. The lysates were 
immunoprecipitated with the respective antibodies as is indicated in Fig. 21b (indicated 
on the left). Coprecipitated proteins were detected by Western blot using anti – 
ARC92/ACID-1 (9C2) and anti-LANA-1 antibodies (Fig. 21b, indicated on the right). The 
two C-terminal deletion mutants L25 and L26 were still able to precipitate the 
endogenous ARC92/ACID-1 protein (Fig. 21b), which demonstrated that the region 
between 1006 and 1162 AA at the C-terminus of LANA-1 is not mandatory for the 
interaction with the Mediator. 
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Fig. 21: The C-terminal LANA-1 domain is not mandatory for the interaction with the 
Mediator protein ARC92/ACID1. 
(a) Schematic diagram of the LANA-1 C-terminal deletion constructs used in the CoIP 
experiment shown. The ability to bind to ARC92/ACID-1 is summarized on the right. (b) The C-
terminal domain of LANA-1 is not mandatory for the interaction with ARC92/ACID1 in CoIP. 
Plasmids encoding the LANA-1 mutants were transfected into HEK 293 cells, 
immunoprecipitated as indicated, separated by SDS-PAGE, blotted, and examined by 
immunostaining (top two panels, anti-LANA-1; lower two panels, anti-ARC92/ACID1). 
 
 
In order to assess which domain of LANA-1 interacts with ARC92/ACID-1, a set of 
different LANA-1 GST-fusion mutants was used. The carboxy-terminally tagged deletion 
mutants of LANA-1 used in the GST pull-down assay are illustrated in Fig. 22a. A 
schematic representation of the GST-tagged LANA-1 mutants pGL9, pGL12 and pGL13 
is shown in Fig. 22b. The pGL9 construct expresses the N- plus C-terminus of LANA-1 
protein without the middle domain. pGL12 expresses the C-terminal domain of LANA-1 
and pGL13 the N-terminal domain of LANA-1.  
a 
b 
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The GST alone and GST-tagged proteins were expressed in BL21 bacteria, as 
described in Materials and Methods, and equivalent amounts were used in GST pull-
down experiments. The GST-tagged proteins were immobilized with glutathione beads 
and incubated overnight with cell lysates of HEK 293 cells transfected with a plasmid 
expressing ARC92/ACID-1. After SDS-PAGE, bound proteins were assessed by 
Western blot analysis using an anti-ARC92/ACID-1 antibody (Fig. 22c, top panel). 
The GST alone didn’t precipitate ARC92/ACID-1. None of the C-terminal fragments of 
LANA-1 precipitated ARC92/ACID-1 (Fig. 22c, top panel). This GST pull-down 
experiment thus confirmed that the C-terminus of LANA-1 does not bind to the Mediator 
complex.  
The Western blot analysis demonstrated that the LANA-1 mutants pGL9 and pGL13 still 
bound to ARC92/ACID-1, whereas the mutant pGL12 lacking the N-terminal domain did 
not, indicating that the N-terminal domain is responsible for the binding to the 
ARC92/ACID-1 subunit of the Mediator complex (Fig. 22c). 
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Fig. 22: The N-terminal domain of LANA-1 binds to the Mediator protein ARC92/ACID1. (a) Schematic 
diagram of the C-terminal LANA-1 fragments expressed as fusion proteins. (b) Schematic representation of 
the LANA-1 deletion constructs pGL9, pGL12 and pGL13. (c) The N-terminal LANA-1 domain interacts with 
ARC92/ACID1 in GST pull-down assays. None of the C-terminal fragments of LANA-1 precipitated 
ARC92/ACID-1 in GST pull-down assays. The GST-tagged proteins expressed in BL21 bacteria and bound 
to glutathione beads were incubated overnight with the cell lysates of HEK 293 cells transfected with 
ARC92/ACID1. The binding reaction was analysed by Western blot using an anti-ARC92/ACID1 antibody 
(top panel). The GST-LANA-1 fusion proteins used in the binding are shown on a Coomassie blue-stained 
SDS-polyacrylamide gel. 
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4. Discussion 
 
4.1. ORFeome-based arrays in eukaryotic expression vectors - a new approach to 
screen for the function of viral genes  
KSHV is the eighth and the most recently identified Human Herpesvirus. Currently 89 
genes have been identified in the long unique region of the viral genome. So far, 
approximately 50% of the KSHV genes have no function assigned. An emerging 
challenge is to rapidly uncover the functions of previously uncharacterised viral genes 
and to discover viral proteins that alter cellular physiology. As an alternative strategy to 
DNA microarrays for transcriptional profiling and to yeast two-hybrid arrays for the 
determination of protein-protein interactions, a system for the functional screening of a 
large number of viral gene products in mammalian cells in parallel has been developed 
in this thesis. 
In the present study, the generation of a KSHV array consisting of all ORFs of KSHV 
cloned into an eukaryotic expression vector by recombinatorial cloning was presented. 
The expression of KSHV proteins in mammalian cells allows their analysis in the natural 
host cell. The effect of viral proteins on the cellular physiology can be investigated by a 
variety of functional assays. The KSHV array cloned in an eukaryotic expression vector 
can be screened by simple detection methods for diverse cellular phenotypes to assign 
functions to previous uncharacterised viral proteins. For example, the KSHV ORFeome 
cloned into the eukaryotic expression vector can be used for systematic analyses of 
virus-host interaction, protein localization, protein phosphorylation or apoptosis 
induction. To identify viral gene products that induce cytoskeletal changes, the array 
could be examined for cells with abnormal morphology by immunofluorescence. In this 
study, the KSHV array was screened for the activation of signalling pathways by 
cotransfection of the individual viral ORFs with luciferase reporter vectors. It was shown 
by the screening for viral proteins activating signalling pathways that this strategy is a 
powerful approach and an efficient alternative.  
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4.2. LANA-1 was identified as an activator of SRE 
There are several reports on KSHV proteins which modulate cell signalling 
pathways9,22,104,108,117. However, our study is the first in which all genes of a complete 
organism were systematically screened for a modulation of cell signalling pathways. 
Since SRE and AP-1 binding sites are important regulatory element of many cellular 
genes involved in cell growth, differentiation and development, the KSHV array was 
screened for KSHV proteins activating promoters via SRE and AP-1. Transient 
transfection experiments in HEK 293 cells identified LANA-1 as a strong activator of 
promoters containing SRE (Fig. 12a). The effect of LANA-1 on SRE was dose-
dependent, supporting its specificity (Fig. 13a). LANA-1, the protein product of the open 
reading frame ORF73, is a latent viral protein expressed in all KSHV-infected cells 
investigated so far79,80,121. Previous studies indicated that LANA-1 shares functions with 
both EBV nuclear antigens EBNA-1 and EBNA-261. LANA-1 is essential for the 
maintenance of viral episomes by binding to the two 17-bp nucleotide motifs LBS 1 and 
2 present in the terminal repeat of the KSHV genome. It associates with histone H1 in 
BCBL-1 cells and tethers the viral episome to the host chromatin36. Moreover, LANA-1 is 
a multifunctional protein which interacts with the p53 and RB tumor suppressor proteins, 
blocks apoptosis and stimulates cellular transformation49,120.  
In the present study, it was shown that LANA-1 is able to activate a promoter containing 
a single wild-type SRE binding site derived from c-fos (Fig. 17). The expression of c-fos 
may affect the subsequent expression of other genes involved in the regulation of cell 
growth, differentiation, or transformation4,60,83. Recently, it was found that KSHV 
infection leads to an upregulation of the c-fos gene (Gao et al., personal 
communication). Moreover, mutational analysis of the c-fos promoter identified SRE as 
the dominant cis-acting element responding to KSHV. A number of experiments have 
suggested that an aberrant production of the c-fos protein can lead to oncogenesis. 
Thus, LANA-1 may be a carcinogenic cofactor by causing aberrant c-fos production. In 
KSHV infection, LANA-1-related SRE activation could contribute to the activation of cell 
division and to the stimulation of viral transcription. 
 
In HEK 293 cells stably transfected with LANA-1, 33% of the upregulated genes have a 
SRE binding site in their promoters2. The following genes belong to this group: 
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• Transducer 1 of ERB-B2 
• osteoclast stimulating factor 1 
• TGFB inducible early growth response factor 
• DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
 
In BJAB B-cell line stably transfected with LANA-1 the picture is similar but not exactly 
the same: about 23% of the upregulated genes have a SRE binding motif in their 
promoters2. The following genes belong to this group:  
• POU domain, class 2 
• transcription factor 2  
• nuclear factor (erythroid-derived 2)-like 3 
• FK506 binding protein 5 
• cell division cycle 25A 
• DnaJ (Hsp40) homolog, subfamily A, member 2 
• major histocompatibility complex, class II, DR beta 1 
• B-cell lymphoma 6 protein 
• ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast)  
• mitogen-activated protein kinase-activated protein kinase 2  
• neuroblastoma RAS viral (v-ras) oncogene homolog 
• GM2 ganglioside activator protein 
• cytochrome b-245, beta polypeptide 
• ubiquitin C  
• phosphoribosyl pyrophosphate synthetase 1  
• elastase 2A  
• solute carrier family 25 
 
In cells infected with KSHV, similar observations can be obtained. KSHV induces a 
transcriptional reprogramming of blood vascular (BEC) to lymphatic endothelial cells 
(LEC), which is similar to the expression profile of KS tumors68,160. Eleven of 33 
upregulated genes detected in these cells contain a SRE binding site in their promoter: 
• GIPC2 (PDZ domain protein) 
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• UBD (ubiquitin D) 
• FST (follistatin) 
• TNFSF10 (tumor necrosis factor superfamily 10) 
• SULF1 (sulfatase 1) 
• GHR (growth hormone receptor) 
• SEPP1 (selenoprotein P, plasma 1) 
• IL6ST (interleukin 6 signal transducer) 
• IL7  
• CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1-biliary 
glycoprotein) 
• CH25H (cholesterol 25-hydroxylase) 
These data suggest that LANA-1-related SRE activation might be important in the 
regulation of KSHV infection and tumorigenesis. 
 
4.3. LANA-1 is a promiscous but selective transcriptional modulator acting in a 
cell-type specific manner 
In DG75 and Jurkat T cells the activation of SRE by LANA-1 was not enhanced (data not 
shown). Several possible mechanisms might explain this observation. It could be that 
LANA-1 targets promoters with SRE via cellular proteins, which are specific for the type 
of cell line used. It could also be that LANA-1 binds to an inhibitory factor in B- and T-cell 
lines which is not present in HEK 293 cells and HeLa cells. In fact, under our 
experimental conditions, a significant activation of SRE in B- and T-cell lines was not 
detected (data not shown).  
Several studies showed that LANA-1 can both activate and repress transcription of 
cellular, as well as viral promoters. Moreover, in Cos-7 cells LANA-1 can activate 
transcription directed by a wide array of simple, synthetic promoters containing binding 
sites for the cellular proteins ATF, AP-1, CAAT, or Sp1, linked to a TATA box123. LANA-1 
activates the HIV-1 LTR promoter in BJAB cells71 but represses the same promoter in 
Cos-7 cells123. In both cases the modulation of transcription by LANA-1 is mediated via 
the NF-κB binding site in the HIV-1 LTR promoter. These reports suggest that the 
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interaction of LANA-1 with the cellular transcription apparatus is very likely to be cell-
type specific. 
In the present study, a set of promoters was compared for transcriptional modulation by 
LANA-1. LANA-1 was suppressive for the promoters containing AP-1 and NF-kB binding 
sites, and for the IL-6 promoter (Fig. 14). It has been reported that LANA-1 activates the 
cellular IL-6 promoter via the AP-1 binding site in HEK 293 cells3. In the present study, 
however a very strong activation of AP-1 by LANA-1 was not obtained (Fig. 13). The 
different outcome is probably caused by the fact that An and colleagues used a 
luciferase plasmid containing different AP-1 binding sites than in the reporter plasmid 
used in our study. The transcriptional repression of the promoter with NF-κB binding 
sites and the HIV-1 LTR promoter by LANA-1 observed in our experimental system 
corresponds to reported data on repression of these promoters by LANA-1 in Cos-7 
cells123 (Fig. 13).  
In the present study, LANA-1 also activated a reporter plasmid containing the ISRE 
element, which is responsive to type 1 interferons133. This effect was seen in HEK 293 
cells but not in DG75 or Jurkat T cells, which suggests a cell type specific behaviour of 
LANA-1. In a microarray screen of cellular cDNAs after KSHV infection, a robust 
increase in the expression of IFN-induced genes is observed in human adult dermal 
microvascular endothelial cells (HMVEC) and human foreskin fibroblast (HFF) cells, 
whereas there is a total lack of induction of these genes in BJAB B-cells 109. This 
confirms that KSHV-induced host gene modulation is different in B-cells compared to 
endothelial and fibroblast cells109. 
Interferons (IFNs) are a unique class of cytokines that stimulate an antiviral and 
antitumor response by inducing the expression of a variety of cellular genes. A number 
of genes induced by IFNs participate in cell growth regulation and apoptosis76. The ISRE 
element is activated by a trimer termed ISGF-3 constituted of phosphorylated STAT-1, 
phosphorylated STAT-2, and p48/IRF-9133. Currently, we do not know the biological 
impact of the finding that LANA-1 activates promoters with ISRE, as it contrasts to the 
fact that KSHV encodes several viral interferon regulatory factors (vIRF) that block 
interferon signalling19,20,93,127. These data are preliminary and the relevance of the role of 
LANA-1 in the response to type 1 interferons is investigated in another study in our 
laboratory.  
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In conclusion, our data suggest a cell-type specific manner of transcriptional modulation 
by LANA-1, similar to the published literature. 
 
4.4. The molecular mechanism of the LANA-1-induced SRE activation 
The present study was focused on the evaluation of the molecular mechanism of 
activation of SRE by LANA-1. They are several reports in the literature on viral proteins 
modulating signalling pathways, which lead to an activation of promoters via the SRE 
element (see introduction). However, the mechanism of modulation differs in all of the 
cases described. Therefore, several strategies for investigation of the effect of LANA-1 
on SRE were pursued.  
 
4.4.1. The role of the MEK/ERK-1/2 pathway in the activation of SRE by LANA-1 
It has been reported that the HCV core protein activates the MAPK/ERK-1/2 pathway 
and its downstream target, SRE, in BALB/3T3 cells 50. Since MAPKs take part in one of 
the main cascades leading to an activation of promoters with SRE binding sites, the 
question was addressed whether LANA-1–induced activation of SRE is dependent on 
MAPK activity. To answer the question the phosphorylation of MEK1/2 kinases in HEK 
293 transiently expressing LANA-1 was evaluated in the presence or absence of specific 
MEK1/2 inhibitors. Two different chemicals were used, PD98059 and U0126. PD98059 
is known to block the phosphorylation of MEK 1 by upstream kinases and U016 inhibits 
both MEK1 and MEK2 phosphorylation. Since both of the inhibitors considerably 
decreased the activation of SRE by LANA-1 (Fig. 15b), an important role of MEK1/2 
kinases in LANA-1-related SRE activation was suggested. By Western blot analyses it 
was demonstrated that LANA-1 enhanced the phosphorylation of MEK1/2 in HEK 293 
cells (Fig. 15c, line 3). ERK1/2 are phosphorylated by activated MEK1/2 and ELK-1, 
which is one of the transcription factors binding to SRE, is a substrate of ERK1/2 
kinases. In a p44/42 MAP kinase assay an increased phosphorylation of ELK-1 at 
Ser383 in LANA-1 transfected cells in vitro was observed, which was even stronger than 
the positive control ERK-2 (Fig. 16). These observations indicate that the MEK/ERK 
cascade might play an important role in the LANA-1-induced activation of SRE.  
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4.4.2. Does the activation of SRE by LANA-1 require the binding to specific 
transcription factors? 
A luciferase assay with SRE reporter plasmids with mutated binding sites for SRF and 
TCF respectively revealed that LANA-1 could activate the SRE element via both SRF 
and TCF (Fig. 17). LANA-1 is located in the nuclei of KSHV-infected cells. Therefore, it 
is possible that LANA-1 activates the promoter containing SRE via direct binding to DNA 
or one of the two transcription factors SRF or TCF. An EMSA experiment demonstrated 
that LANA-1 does not bind directly to SRE (data not shown). Subsequently, it was 
evaluated whether LANA-1 interacts with specific transcription factors. Co-
immunoprecipitation experiments with several transcription factors including ELK-1, 
SRF, STAT-1 and SpiB showed that LANA-1 interacts with SRF (Fig. 18). LANA-1 was 
immunoprecipitated with an antibody specific for SRF (Fig. 18a, line 4, upper panel). 
However, the reciprocal experiment did not work. This could be due to the 
stochiochemistry of the complex formed between the two interacting proteins (SRF and 
LANA-1), which prevents the binding of the antibody to the specific epitope. LANA-1 
interacts with a variety of transcriptional regulators including the nucleic mitogen-
activated kinase Ring399,116, ATF/CREB291 and CBP90, and acts as a transcriptional 
activator or suppressor of cellular and viral genes.  
An interaction between LANA-1 and STAT-1 similar to SRF was not detected, indicating 
either technical restraints or that LANA-1-mediated ISRE activation is caused by another 
mechanism, possibly as a secondary phenomenon. The interaction of LANA-1 with SRF, 
however, does not seem to be mandatory for the LANA-1 related SRE activation, since 
the c-fos promoter with the mutated SRF binding site could still be activated by LANA-1 
(Fig. 17). On the other hand, in luciferase reporter gene experiments LANA-1 acted as 
an enhancer of RAS V12-induced transcriptional activation of the SRE promoter (Fig. 
14). When LANA-1 was cotransfected together with RAS V12 the activation of the 
promoter was 2-fold stronger than the induction with RAS V12 alone. A similar effect 
was seen with the promoter ISRE promoter. A prestimulated ISRE promoter was further 
activated when LANA-1 was cotransfected into the cells. The presence of LANA-1 led to 
4-fold stronger induction of the reporter vector compared to the stimulation with IFN α 
alone (Fig. 14). This observation and the studies published so far led us to the 
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hypothesis that LANA-1 could have a more global effect on cellular gene expression 
through a direct interaction with the basal transcription machinery. 
 
4.4.3. LANA-1 meets the Mediator 
The Mediator is a multi-subunit complex of approximately 2 megadaltons capable of 
responding to different activators95,107,119. It plays a key role in bridging DNA-bound 
activators of chromatin remodeling with the general transcriptional machinery, 
particularly RNA polymerase II88. Several other viral proteins are known to interact with 
the Mediator and thereby modulate transcription: adenovirus large E1A protein interacts 
with the Sur-2 subunit from the Mediator complex via its E1A-CR3 zinc finger159, ORFA 
protein of Walley dermal sarcoma virus co-immunoprecipitates with Cdk8 and cyclin C 
which are part of the Mediator129 and herpes simplex virus type 1 VP16 interacts with 
ARC92/ACID1 via its activation domain102. In this study, it was shown by luciferase 
assays and CoIP that LANA-1 interacts with the Mediator (Fig. 19 and 20). The 
interaction between LANA-1 and the Mediator complex was detected by CoIP using 
antibodies against several different Mediator subunits including ARC92/ACID1, PCQAP 
and Sur-2 (suppressor of ras) (Fig. 19).  
Transcriptional activation by the herpesviral VP16 protein requires the Mediator subunit 
ARC92/ACID-1 (MED 25)14,102. Similar to LANA-1, VP-16 also participates in the 
activation of type I-interferon inducible promoters (Meisterernst et al. unpublished). 
Overexpression of the ARC92/ACID1 NTD domain strongly reduces the activation of 
pGLMRG5 (synthetic promoter containing five GAL4-binding sites upstream of a core 
promoter) by GAL4-VP-16102. This effect is a result of the direct binding of NTD to the 
Mediator and the loss of the endogenous ARC92/ACID-1 from the Mediator complex102 
(Fig. 20a). In this study, the overexpressed ARC92/ACID1 NTD domain inhibited the 
LANA-1-induced activation of promoters carrying SRE and ISRE, but not the activation 
of these promoters by their respective positive controls (Fig. 20b). This outcome 
indicates that it is very likely the viral transactivator LANA-1 to use the same Mediator 
subunit (ARC92/ACID-1) as the HSV-1 VP16 protein102 (Fig. 20). The fact that NTD did 
not block the activation of SRE by RAS V12 confirmed the specificity of the 
transcriptional modulation by the overexpressed negative dominant domain of 
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ARC92/ACID-1 (Fig. 20b). The activation of endogenous immediate early genes in 
response to the RAS-RAF-MEK-ERK pathway occurs via another subunit of the 
Mediator complex, Sur-2149.  
LANA-1 has a complex domain structure (Fig. 23). The N-terminal domain is proline-rich 
and a binding site for SH3-domain proteins. The N-terminal domain of LANA-1 contains 
a nuclear localization sequence (NLS) and binds the methyl CpG-binding protein 
MeCP284,85. The acidic internal repeat domain (IRD) is mandatory for the transcriptional 
activation of cellular and viral promoters123. The C-terminal domain contains a leucine 
zipper oligomerization sequence and a second NLS61. In order to map the domain of the 
LANA-1 protein, which interacts with the ARC92/ACID-1 subunit, GST pull-down 
experiments were carried out (Fig. 22). These experiments revealed that the N-terminal 
domain of LANA-1 interacts with the Mediator subunit ARC92/ACID1 (Fig. 22). Co-
immunoprecipitations using C-terminal deletion mutants of LANA-1 confirmed that the C-
terminus of LANA-1 is not mandatory for this interaction (Fig. 21). 
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N-terminal domain C-terminal domainIRD (acidic domain)
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Transcriptional modulation of 
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Binding to RING3
IRD (internal repeat domain)  
 
  
Fig. 23: The domain structure of LANA-1. The three main domains of the LANA-1 protein, 
namely N-terminal, central and C-terminal, are indicated. 
 
 
In previous studies the corepressor protein SAP30 was identified as a LANA-1 binding 
protein in an Y2H screen85. SAP30 is a constituent of a large multicomponent complex 
that recruits histone deacetylases to the promoter. LANA-1 binds to two other members 
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of the corepressor complex, mSin3A and CIR, via its N-terminal domain and represses 
the expression from the latent EBV Qp and Cp promoters85. This indicates that LANA-1 
can mediate a transcriptional repression through the recruitment of the mSin3 
corepressor complex 85. In our study, it was shown that LANA-1 activates transcription of 
promoters with SRE and ISRE binding sites by binding to the Mediator complex via its 
N-terminal domain. Based on these two observations, one could speculate that the 
transcriptional modulator LANA-1 uses the same N-terminal domain to bind either a 
corepressor complex or the Mediator. Our investigations together with published data 
suggest that LANA-1 can switch between repression and activation of a variety of 
promoters. Like many viral regulators LANA-1 interacts with cellular proteins to recruit 
the machinery needed to support viral propagation. Complexes with LANA-1 may have 
extended substrate specificity or changes in activity toward specific transcription factors, 
thereby increasing or decreasing transcription from a subset of promoters. In vivo, 
binding affinities are probably modulated differentially at promoters with SRE and ISRE 
binding sites by posttranscriptional modifications and by interactions with different 
cofactors and accessory proteins. Such mechanisms may have oncogenic potential 
through the enhancement or inhibition of proto-oncogene or tumor suppressor 
expression. It is anticipated that information derived from the function of LANA-1 will also 
help to delineate the role of the Mediator complex in the control of transcription. 
 
4.4.4. Proposed model for action of the transcriptional modulator LANA-1  
A schematic model for the molecular mechanism of LANA-1-mediated activation of 
promoters containing the SRE element is presented in Fig. 24. LANA-1 interacts with the 
Mediator most likely via a direct binding to the ARC92/ACID-1 protein. At promoters with 
an SRE element, LANA-1 additionally binds to SRF. 
There are still open questions, for example which domain of the Mediator subunit 
ARC92/ACID-1 binds to the N-terminal domain of LANA-1 and which part of LANA-1 
interacts with SRF. The answers of these questions will shed light on how this complex 
of viral and cellular proteins assemble on SRE promoters and drive the transcription.  
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Fig. 24: Proposed model for action of LANA-1. 
The N-terminal domain of LANA-1 interacts with ARC-92/ACID-1 of the Mediator complex. The 
Mediator transfers the activation signal to the polymerase II. At promoters with an SRE element, 
LANA-1 additionally binds to the specific transcription factor SRF. 
 
 
The activation of the MAPK/ERK pathway and the interaction of LANA-1 with the 
Mediator complex presented in this study can be independent phenomena. Alternatively, 
both effects could be cooperatively linked. The RAF/MEK1/2 pathway leads to an 
interaction between ELK-1 and the Mediator subunit Sur-2 that transfers the activation 
signal to the basal transcription machinery149. The results presented in this study 
indicate that LANA-1 leads to a phophorylation of ELK-1 (Fig. 16), binds to SRF (Fig. 
18a), and coprecipitates with the Sur-2 protein of the Mediator complex (Fig. 19c). This 
suggests that the two phenomena are likely to be connected to each other.  
It is possible that other proteins of cellular or viral origin contribute to the high complexity 
of this effect and modify it in a specific way in different cell types. Our study 
demonstrated that LANA-1 associates and cooperates with the Mediator and thus 
influences the basal transcription machinery on promoters with SRE and ISRE binding 
sites. In cells infected with KSHV other viral proteins might modulate the effect of LANA-
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1. The RTA protein of KSHV, which acts as a molecular switch for lytic reactivation, 
activates the expression of viral promoters by recruiting the Mediator complex64. It may 
also be that RTA and LANA-1 synergistically interact to regulate the virus infection.  
 
Currently, neither the stochiochemistry of the interaction of LANA-1 with the Mediator 
complex nor if additional cellular factors are involved is known. Further studies are 
necessary to define the specific order of transcription factor assembly on the promoters 
with SRE and ISRE binding sites and to clarify the role and function of LANA-1 in this 
process. These analyses, however, will not only provide insight into a crucial step of KS 
oncogenesis, but also shed light on the way how transcriptional processes work in non-
transformed cells. An increased understanding of signalling pathways induced by KSHV 
proteins may eventually lead to the development of novel therapies to control KS 
lesions. 
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5. Materials and Methods 
 
5.1. Materials 
 
5.1.1. Equipment 
Bacterial Shaker  Kühner, Bürsfelden, Switzerland 
Balances  Sartorius, Göttingen, Germany 
Centrifuge GP Beckman, Palo Alto, USA 
Centrifuge J2-21 Beckman, Palo Alto, USA 
Centrifuge Varifuge 3.0R Heraeus, Hanau, Germany 
Centrifuge Minifuge RF Heraeus, Hanau, Germany 
Centrifuge Labofuge T  Heraeus, Hanau, Germany 
Centrifuge, refrigerated and non-
refrigerated  
Heraeus, Hanau, Germany 
Confocal laser scanning microscope  Leica, Bensheim, Germany 
Confocal laser scanner  Leica, Bensheim, Germany 
Eagle eye  Stratagene, The Netherlands 
Elisa Reader  Tecan Labinstruments, Germany 
Film developing machine  Optimax Typ TR MS Laborgeräte, 
Germany 
Fluorescence/light microscope 
Axiovert 35  
Zeiss, Oberkochen, Germany 
Fluorescence/light microscope 
Axiovert 200M  
Zeiss, Oberkochen, Germany 
Fridge (4°C)  Liebherr, Ochsenhausen, Germany 
Freezer (-20°C)  Liebherr, Ochsenhausen, Germany 
Freezer (-80°C)  Forma Scientific, Inc., Marietta, USA 
Cryo 1°C Freezing Container  Nalgene Nunc, Wiesbaden, Germany 
Gel dryer  Bio-Rad, Munich, Germany 
GelAir drying system  Bio-Rad, Munich, Germany 
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Incubators for cell culture (37°C)  Forma Scientific, Inc., Marietta, USA 
Inverted microscope TMS  Nikon, Düsseldorf, Germany 
Laminar Flow Hood Steril Gard II A/B3 The Baker Company, USA 
Magnetic stirrer with heating block  Janke & Kunkel, Staufen, Germany 
Microwave  AEG, Berlin, Germany 
Overhead mixer  Heidolph, Schwabach, Germany 
PCR Thermal Cycler GeneAmp 2400  Perkin Elmer, Weiterstadt, Germany 
pH-Meter  WTW, Weilheim, Germany 
Photometer Gene Quant II  Pharmacia/LKB, Freiburg, Germany 
Pipettes Gilson, Villies Le Bel, France 
Eppendorf, Hamburg, Germany 
Pipetting aid  Technomara, Zürich, Switzerland 
Electrophoresis Power supply EPS200 Amersham-Pharmacia, Germany 
Sonifier 450  Branson Ultrasonics Corp., Danbury, USA 
Thermomixer  Eppendorf, Hamburg, Germany 
UV-transilluminator (366 nm) 
(254 nm) 
Vetter, Wiesloch, Germany 
Konrad Benda, Wiesloch, Germany 
Vortex mixer IKA Works, Inc, Wirmington, USA 
Water bath Julabo, Seelbach, Germany 
GFL, Burgwedel, Germany 
 
5.1.2. Reagents 
 
5.1.2.1. Chemicals 
Acetic Acid  Roth, Karlsruhe, Germany 
Acrylamide/Bisacrylamide 37,5/1  
(Rotiphorese Gel 30) 
Roth, Karlsruhe, Germany 
Agar for plates  BD Biosciences Clontech, Heidelberg, 
Germany 
Agarose electrophoresis grade  Invitrogen, Karlsruhe, Germany 
Ammonium persulfate (APS)  Sigma, Munich, Germany 
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Ampicillin   Roche Diagnostics, Germany 
Bacto peptone  BD Biosciences Clontech, Germany 
Bacto tryptone  BD Biosciences Clontech, Germany 
Bacto yeast extract BD Biosciences Clontech, Germany 
Bromophenol blue   Serva, Heidelberg, Germany 
Bovine serum albumin (BSA)  Sigma, Munich, Germany 
Calcium chloride  Merck, Darmstadt, Germany 
Chloramphenicole  Sigma, Munich, Germany 
Coomassie brilliant blue R-250   Bio-Rad, Munich, Germany 
Dimethylsulfoxide (DMSO)  Merck, Darmstadt, Germany 
Disodiumhydrogenphosphate  Merck, Darmstadt, Germany 
Dithiothreitol (DTT)  Roth, Karlsruhe, Germany 
dNTPs  Roche Diagnostics,Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM)  
Gibco BRL, Karlsruhe, Germany 
Ethanol (EtOH)  Riedel-de Haën, Seelze, Germany 
Ethidium bromide Sigma, Munich, Germany 
Ethylenediamintetraacetate disodium 
salt (EDTA) 
Roth, Karlsruhe, Germany 
Ethylene glycol   Sigma, Munich, Germany 
Fetal calf serum (FCS)   Gibco BRL, Karlsruhe, Germany 
Glucose  Merck, Darmstadt, Germany 
Glutathione-Sepharose 4B  Amersham-Pharmacia, Germany 
Glycerol   Roth, Karlsruhe, Germany 
Glycine  Serva, Heidelberg, Germany 
Histogel  Linaris, Germany 
Hydrochloric acid (HCl)  Merck, Darmstadt, Germany 
Interferon (IFN) α  PBL Biomedical Laboratories, USA 
Ionomycin  Sigma, Munich, Germany 
Isopropanol   Riedel-de Haën, Seelze, Germany 
Isopropylthio-b-D-galactosid (IPTG)  Roth, Karlsruhe, Germany 
Kanamycin    Serva, Heidelberg, Germany 
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L-glutamine  Gibco BRL, Karlsruhe, Germany 
L-Glutathione (reduced)  Sigma, Munich, Germany 
Magnesium chloride   Merck, Darmstadt, Germany 
Magnesium sulfate   Merck, Darmstadt, Germany 
2-mercaptoethanol  Merck, Darmstadt, Germany 
Methanol  Merck, Darmstadt, Germany 
N-butyrate  Sigma, Munich, Germany 
Nonidet P40 (NP-40)  Fluka, Seelze, Germany 
Pefabloc   Roche Diagnostics,Germany 
Polyethylene glycol (PEG 1000)  Sigma, Munich, Germany 
Penicillin-Streptomycin   Gibco BRL, Karlsruhe, Germany 
Phenylmethylsulfonfluoride (PMSF)  Roche Diagnostics, Germany 
Phosphate buffered saline (PBS) 
Dulbecco’s  
Gibco BRL,Germany 
Ponceau S   Sigma, Munich, Germany 
Potassium acetate   Riedel-de Haën, Seelze, Germany 
Potassium chloride  Merck, Darmstadt, Germany 
Protein G-Sepharose Fast Flow  Amersham-Pharmacia, Germany 
Rosswell Park Memorial Institute 
(RPMI)1640  
Gibco BRL, Karlsruhe, Germany 
SD Base medium  BD Biosciences Clontech, Germany 
Skim milk powder  Merck, Darmstadt, Germany 
Sodium acetate  Riedel-de Haën, Seelze, Germany 
Sodium azide  Serva, Heidelberg, Germany 
Sodium chloride   Riedel-de Haën, Seelze, Germany 
Sodium dodecylsulfate (SDS)  Merck, Darmstadt, Germany 
Sodium hydroxid  J.T.Baker B.V., Deventer, Holland 
Sorbitol    Sigma, Munich, Germany 
Tetramethylethylenediamin (TEMED)  Amersham-Pharmacia, Germany 
12-O-tetradecanoylphorbol-13-acetate 
(TPA)  
Sigma, Munich, Germany 
Tris(hydroxymethyl)aminomethan Roth, Karlsruhe, Germany 
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(Tris)  
Triton X-100   Serva, Heidelberg, Germany 
Trypsin  Gibco BRL, Karlsruhe, Germany 
Tween 20  Merck, Darmstadt, Germany 
Western Blue® Stabilized Substrate 
for alkaline phosphatase 
Promega, Mannheim, Germany 
 
5.1.3. Additional materials 
Autoradiography films BIOMAX-MR  Eastman-Kodak, USA 
Cell culture plastic ware  Greiner, Nürtingen, Germany 
Nunc, Wiesbaden, Germany 
Falcon/Becton Dickinson, Germany 
Filter paper (3 mm)  Whatman Ltd., Maidstone, England 
Glass slides for IF  Marienfeld, Germany 
Protran nitrocellulose transfer 
membranes  
Schleicher & Schuell, Germany 
Sterile filter units Millipore 
 
5.1.4. Enzymes 
AmpliTag Gold® DNA polymerase   Applied Biosystems, USA 
Calf intestinal alkaline phosphatase (CIP)  New England Biolabs 
Expand High Fidelity PCR system  Roche 
Klenow fragment   Roche 
Pfu DNA polymerase  Stratagene 
Restriction enzymes  New England Biolabs, Roche 
RNase A   Roche 
T4 DNA ligase   New England Biolabs 
T4 DNA polymerase   New England Biolabs 
T4 polynucleotide  kinase New England Biolabs 
Taq polymerase  Roche 
Vent Polymerase   New England Biolabs 
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5.1.5. General buffers 
HeBS (HEPES-buffered saline) solution, 2x: 16.4 g NaCl, 11.9 g HEPES, 0.21 g 
Na2HPO4 in 1 L dH2O. Titrate to pH 7.05 with 5 N NaOH. Filter sterilize through a 
0.45-µm nitrocellulose filter (Millipore). Store in aliquots at –20°C.  
TBE (Tris/borate/EDTA) electrophoresis buffer (10x): 890 mM Tris base, 890 mM 
boric acid, 20 mM EDTA. 
SDS electrophoresis (Tris/glycine) buffer, 5x: 15.1 g Tris base, 72.0 g glycine, 5.0 
g SDS in 1 L dH2O. 
SOC: 2.0 g Bacto-Tryptone, 0.5 g Bacto-Yeast extract, 1 ml 1 M NaCl, 0.25 ml 1.M 
KCl, 1 ml 2 M Mg stock (1 M MgCl2 – 6 H2O, 1 M MgSO4 – 7 H2O), 1 ml 2 M Glucose, 
up to 100 ml ddH2O. Added Bacto-Tryptone, Bacto-Yeast extract, NaCl and KCl to 97 
ml dH2O. Stirred to dissolve. Autoclaved and cooled to RT. Added 2 M Mg stock and 
2 M Glucose, each to a final concentration 20 mM. Filtered the complete medium 
through a 0.2 µm filter. The pH should be 7.0. 
LB medium was prepared according to Sambrook and Russel: 10 g Bacto tryptone, 5 
g Bacto yeast extract and 5 g NaCl for 1 L medium. For agar plates 15 g agar was 
added. 
Adjusted the pH to 7.0 with NaOH (~200 ul 5 M NaOH). Autoclaved and allowed to 
cool to 50°C before adding antibiotics. Autoclaved media was stored at room 
temperature if top is tightened and then had been used by microwaving at 70 % for 
~15 min. For liquid media leave out the agar. 
 
5.1.6. Viruses 
Recombinant vaccinia virus T7 (vT7) expressing T7 polymerase was provided by 
the NIH reagent program (Fuerst et al., 1986).  
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5.1.7. Bacterial strains 
BL21 RIL kindly provided by Dr. K.-P. Hopfner, München, Germany 
DH10B obtained from Invitrogen, Germany 
DH5α obtained from Gibco BRL, Karlsruhe, Germany 
 
5.1.8. Cell lines 
BCBL-1 KSHV positive body-cavity-based lymphoma cell line  
BJAB EBV negative human B lymphoblastoid cell line  
DG75 EBV positive human Burkitt lymphoma cell line 
HEK 293 human embryonic kidney cells 
HeLa human epithelial cell line originating from a cervical carcinoma 
Jurkat human T lymphoblastoid cell line 
 
5.1.9. Oligonucleotides 
 
5.1.9.1. Oligonucleotides used for generation of the KSHV PCR products cloned 
into pDONR207 by BP reaction (see 5.2.2.7 and 5.2.2.8).  
attB1 internal for AAAAAGCAGGCTCCGCCATGXXXXXXXXXXXXXXXXXXX 
attB1 internal rev AGAAAGCTGGGTCTAXXXXXXXXXXXXXXXXXXXX 
attB1 external for GGGGACAAGTTTGTACAAAAAAGCAGGCT 
attB2 external rev GGGGACCACTTTGTACAAGAAAGCTGGGT 
yellow box: attB1 sequence 
red letters: Kozak sequence 
bold letters: ATG (for) and stop (rev) codon 
XXXXX: homologous for and rev sequence 
Internal primers: 
Orf4 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
GCCTTTTTAAGACAAAC 
Orf4 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGCTAACGA
AAGAACAGATAG 
Orf6 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
GCGCTAAAGGGACCAC 
Orf6 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGCTACAAAT
CCAGGTCAGAG 
Orf7 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
Materials and Methods 
 65
GCAAAGGAACTGGCG 
Orf7 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGCTAGACC
TGGGAGTCATTG 
Orf8 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCCGC
CGCACCAATACCATAGC 
Orf8 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGTCACTCC
CCCGTTTCCGG 
Orf9 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
GATTTTTTCAATCCATTTATC 
Orf9 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGCTAGGGC
GTGGGAAAAGTC 
Orf10 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
CAGACAGAGGCAACG 
Orf10 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGTCACGATT
GCATGGGTTC 
Orf11 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
GCGCAGGAGTCAGAG 
Orf11 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGCTAACTG
CGTCCGGTGGC 
K2 for  GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
TGCTGGTTCAAGTTG 
K2 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACTTAT
CGTGGACGTC 
Orf02 for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
GATCCTACACTTTAC 
Orf02 rev  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACGAA
GTCTCACTGAAG 
K3 for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATG
GAAGATGAGGATGTTC 
K3 rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTTAATGAA
ACATAAGGGC 
orf6 for AAAAAGCAGGCTCCATGGCGCTAAAGGGACCAC 
orf6 rev AGAAAGCTGGGTCTACAAATCCAGGTCAGAG 
orf7 for   AAAAAGCAGGCTCCGCCATGGCAAAGGAACTGGCGGC
G 
orf7 rev AGAAAGCTGGGTCTAGACCTGGGAGTCATTGTGG 
Orf70 for  AAAAAGCAGGCTCCGCCATGTTTCCGTTTGTACCTTTA
AG 
Orf70 rev  AGAAAGCTGGGTCTATACTGCCATTTCCATACG 
K4 for  AAAAAGCAGGCTCCGCCATGGACACCAAGGGCATC 
K4 rev  AGAAAGCTGGGTTCAGCGAGCAGTGACTGG 
K4.1 for AAAAAGCAGGCTCCGCCATGTGGAGCATGTGCTGGG 
K4.1 rev AGAAAGCTGGGTCTAGGGGCATAACCCTTTAC 
k4.2 for AAAAAGCAGGCTCCGCCATGCAAATTAGCTTTGCCGAA
G 
K4.2 rev AGAAAGCTGGGTTTATTGAAGCCCAGGCGACC 
K5 for  AAAAAGCAGGCTCCGCCATGGCGTCTAAGGACGTAG 
K5 rev  AGAAAGCTGGGTTCAACCGTTGTTTTTTGGATG 
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K6 for  AAAAAGCAGGCTCCGCCATGGCCCCCGTCCACGTT 
K6 rev  AGAAAGCTGGGTCTAAGCTATGGCAGGCAGC 
K7 for  AAAAAGCAGGCTCCGCCATGGGAACACTGGAGATAAA
AG 
K7 rev  AGAAAGCTGGGTCTACAACTGGCCTGGAGATTG 
Orf 16 for  AAAAAGCAGGCTCCGCCATGGACGAGGACGTTTTGC 
Orf 16 rev  AGAAAGCTGGGTTTATCTCCTGCTCATCGCG 
Orf 17 for  AAAAAGCAGGCTCCGCCATGAGCCTCCTAAGCCCC 
Orf 17 rev  AGAAAGCTGGGTCTACTGCTTGTTCAGGAGC 
Orf 18 for  AAAAAGCAGGCTCCGCCATGCTCGGAAAATACGTGTG 
Orf 18 rev  AGAAAGCTGGGTTTAAACCGCGTTGTTGTTAAAC 
Orf 67 for  AAAAAGCAGGCTCCGCCATGAGTGTCGTTGGTAAGCG 
Orf 67 rev  AGAAAGCTGGGTTTATGACCTTCTCACCAGCGC 
Orf 19 for  AAAAAGCAGGCTCCGCCATGCTGACATCAGAAAGGTC 
Orf 19 rev  AGAAAGCTGGGTTTAAACGACCGCGAGGACC 
Orf 20 for  AAAAAGCAGGCTCCGCCATGTACGAGGTTTTTACAGAC
Orf 20 rev  AGAAAGCTGGGTTCATGGACCTGAACAAGCC 
Orf 21 for  AAAAAGCAGGCTCCGCCATGGCAGAAGGCGGTTTTG 
Orf 21 rev  AGAAAGCTGGGTCTAGACCCTGCATGTCTC 
Orf 22 rev cyt  AGAAAGCTGGGTCTAATAAAGGATGGAAAACAG 
Orf 23 for  AAAAAGCAGGCTCCGCCATGTTACGAGTTCCGGACG 
Orf 23 rev  AGAAAGCTGGGTTTAGACGGTCAATAAAGCG 
Orf 24 for AAAAAGCAGGCTCCGCCATGGCAGCGCTCGAGGG 
Orf 24 rev  AGAAAGCTGGGTTTAGACCAGCGGACGGAC 
Orf 25 for  AAAAAGCAGGCTCCGCCATGGAGGCGACCTTGGAG 
Orf 25 rev  AGAAAGCTGGGTCTAATACACCACCTTGTTTC 
Orf 26 for  AAAAAGCAGGCTCCGCCATGGCACTCGACAAGAGTATA
G 
Orf 26 rev  AGAAAGCTGGGTTTAGCGTGGGGAATACCAAC 
Orf 27 for  AAAAAGCAGGCTCCGCCATGGCGTCATCTGATATTC 
Orf 27 rev  AGAAAGCTGGGTTTATTTAAAATTTAGAATCAAGGGAG
G 
Orf 28 for cyt  AAAAAGCAGGCTCCGCCATTCGCGTGTTCCTGGCGGC 
Orf 28 rev cyt  AGAAAGCTGGGTCTAATCTGGCATGTATATTG 
Orf 29b for  AAAAAGCAGGCTCCGCCATGCTTCAGAAAGACGCCAA
G 
Orf 29b rev  AGAAAGCTGGGTTTATTGTGGGGATATGGGC 
Orf 30 for  AAAAAGCAGGCTCCGCCATGGGTGAGCCAGTGGATC 
Orf 30 rev  AGAAAGCTGGGTTCATTTCGCACCGGTGTC 
Orf 31 for  AAAAAGCAGGCTCCGCCATGTCACAAAACAGAAAGACT
C 
Orf 31 rev  AGAAAGCTGGGTCTACGTATCTTTCGTTGATAG 
Orf 32 for  AAAAAGCAGGCTCCGCCATGGATGCGCATGCTATCAAC
Orf 32 rev  AGAAAGCTGGGTCTAGCCATAGCGGCCTCG 
Orf 33 for  AAAAAGCAGGCTCCGCCATGGCTAGCCGGAGGCGC 
Orf 33 rev  AGAAAGCTGGGTTCAGACATTCGTAAGAGGACC 
Orf 29a for  AAAAAGCAGGCTCCGCCATGCTGCTCAGCCGTCAC 
Orf 29a rev  AGAAAGCTGGGTTTAAGGCCCTGGGCTTACG 
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Orf 34 for  AAAAAGCAGGCTCCGCCATGTTTGCTTTGAGCTCGTG 
Orf 34 rev  AGAAAGCTGGGTTTAGAGTTGGTTGAGTCCATTC 
Orf 35 for  AAAAAGCAGGCTCCGCCATGGACTCAACCAACTCTAAA
AG 
Orf 35 rev  AGAAAGCTGGGTTTAGGGAGTTTCAGGGCAC 
Orf 36 for  AAAAAGCAGGCTCCGCCATGCGCTGGAAGAGAATGG 
Orf 36 rev  AGAAAGCTGGGTTCAGAAAACAAGTCCGCGG 
Orf 37 for  AAAAAGCAGGCTCCGCCATGGAGGCCACCCCCAC 
Orf 37 rev  AGAAAGCTGGGTCTACGGGCTGTGAGGGACG 
Orf 38 for  AAAAAGCAGGCTCCGCCATGGGATTTCTCCTATCTATC 
Orf 38 rev  AGAAAGCTGGGTTTAATAAATTGCTTCTTTATTTTTTTTC
Orf 39 for cyt  AAAAAGCAGGCTCCGCCCGCGTTATAAGGAGCGACTG 
Orf 39 rev cyt  AGAAAGCTGGGTTCTAAATGAATATCATTTGCGTTTC 
Orf 40 for  AAAAAGCAGGCTCCGCCATGGCAACGAGCGAAGAAAC 
Orf 40 rev  AGAAAGCTGGGTCAAGCAGGGACAGTAGGTC 
Orf 41 for  AAAAAGCAGGCTCCGCCATGGCCGGGTTTACTCTG 
Orf 41 rev  AGAAAGCTGGGTTCAAAATAAAGATAAAAGCCTGG 
Orf 42 for  AAAAAGCAGGCTCCGCCATGTCCCTGGAAAGGGCC 
Orf 42 rev  AGAAAGCTGGGTTTATTTTGAAAAAAGGGAAACAATG 
Orf 43 for  AAAAAGCAGGCTCCGCCATGTTGAGGATGAACCCGG 
Orf 43 rev AGAAAGCTGGGTCTATGCACTTCCAGGACAAG 
Orf 44 for  AAAAAGCAGGCTCCGCCATGGACAGCTCGGAAGGG 
Orf 44 rev  AGAAAGCTGGGTTCAGTAGATCAGAGTAGTC 
Orf 45 for  AAAAAGCAGGCTCCGCCATGGCGATGTTTGTGAGGAC 
Orf 45 rev  AGAAAGCTGGGTTCAGTCCAGCCACGGCCAG 
Orf 46 for  AAAAAGCAGGCTCCGCCATGGACGCATGGTTGCAAC 
Orf 46 rev  AGAAAGCTGGGTTTACTGCTCCAACAGGCCC 
Orf 47 for gL AAAAAGCAGGCTCCGCCCATGGGGATCTTTGCGCTATT
TG 
Orf 47 rev gL AGAAAGCTGGGTTTATTTTCCCTTTTGACCTGCG 
Orf 48 for cyt  AAAAAGCAGGCTCCGCCATGGAGGTGTGTATCCCAATT
C 
Orf 48 rev cyt  AGAAAGCTGGGTCCGCCGGAACTCCACATC 
Orf 48 for ext  AAAAAGCAGGCTCCGCCATTACCTCGGACGTGAGAC 
Orf 48 rev ext  AGAAAGCTGGGTTCAATCATACTCATCGTCGG 
Orf 49 for  AAAAAGCAGGCTCCGCCATGACATCGAGAAGGCCCC 
Orf 49 rev  AGAAAGCTGGGTTTATTGTATACTGAACAATGCG 
Orf 50 for  AAAAAGCAGGCTCCGCCATGAAAGAATGTTCCAAGCTT
G 
Orf 50 rev  AGAAAGCTGGGTTCAGTCTCGGAAGTAATTACG 
K8 for  AAAAAGCAGGCTCCGCCATGCCCAGAATGAAGGAC 
K8 rev  AGAAAGCTGGGTCTATACCTGCTGCAGCTG 
Orf 52 for  AAAAAGCAGGCTCCGCCATGGCCGCGCCCAGGGG 
Orf 52 rev  AGAAAGCTGGGTTCAGTCATCAACCCCCGC 
Orf 53 for  AAAAAGCAGGCTCCGCCATGACAGCGTCCACGGTGG 
Orf 53 rev  AGAAAGCTGGGTCTATGCATGGACCACCTCG 
Orf 54 for  AAAAAGCAGGCTCCGCCATGAACAACCGCCGAGGC 
Orf 54 rev  AGAAAGCTGGGTCTAAAACCCAGACGACCCC 
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Orf 55 for  AAAAAGCAGGCTCCGCCATGTCGTCTCCATGGTACAC 
Orf 55 rev  AGAAAGCTGGGTCTATGTCGAACCTATCGCG 
Orf 56 for  AAAAAGCAGGCTCCGCCATGGAGACGACATACCGCC 
Orf 56 rev  AGAAAGCTGGGTTTAACTGGCCAGTCCCACTG 
Orf 57 for  AAAAAGCAGGCTCCGCCATGATAATTGACGGTGAGAG
CC 
Orf 57 rev  AGAAAGCTGGGTTTAAGAAAGTGGATAAAAGAATAAAC 
K9 for  AAAAAGCAGGCTCCGCCATGGACCCAGGCCAAAGAC 
K9 rev  AGAAAGCTGGGTTTATTGCATGGCATCCCATAAC 
K10 for  AAAAAGCAGGCTCCGCCATGGGGTCCTCTGGGACG 
K10 rev  AGAAAGCTGGGTTCAATGTAGACTATCCCAAATG 
K10.5 for AAAAAGCAGGCTCCGCCATGTACCACGTGGGACAGG 
K10.5 rev AAAAAGCAGGCTTTAGTCATCACATGTAACTGAAC 
K11 for  AAAAAGCAGGCTCCGCCATGCACAGTTTGTTTTTTGAA
G 
K11 rev  AGAAAGCTGGGTTTAGTCTCTGTGGTAAAATGG 
Orf 58 for  AAAAAGCAGGCTCCGCCATGTGCCGCCTGGACAGTG 
Orf 58 rev  AGAAAGCTGGGTTTAGCCAACAACTTTATTTATTAC 
Orf 59 for  AAAAAGCAGGCTCCGCCATGCCTGTGGATTTTCACTAT
G 
Orf 59 rev  AGAAAGCTGGGTTCAAATCAGGGGGTTAAATG 
Orf 60 for  AAAAAGCAGGCTCCGCCATGGATTCAGTTGATCGATTT
C 
Orf 60 rev  AGAAAGCTGGGTTCACAAATCGTCAGTCACAC 
Orf 61 for  AAAAAGCAGGCTCCGCCATGTCTGTCCGGACATTTTG 
Orf 61 rev  AGAAAGCTGGGTCTACTGACAGACCAGGCAC 
Orf 62 for  AAAAAGCAGGCTCCGCCATGAAGGTGCAGGCTGAAAA
TG 
Orf 62 rev  AGAAAGCTGGGTTTACAGAAACACAGTCCAGG 
Orf 63 for  AAAAAGCAGGCTCCGCCATGGACGGCACAGACGCTC 
Orf 63 rev  AGAAAGCTGGGTCTATTCGACAAACAGTTTCCG 
Orf 64 for  AAAAAGCAGGCTCCGCCATGGCAGCCCAGCCTCTG 
Orf 64 rev  AGAAAGCTGGGTTCACAAGTACCACTTCTTTATTC 
Orf 65 for  AAAAAGCAGGCTCCGCCATGTCCAACTTTAAGGTGAGA
G 
Orf 65 rev  AGAAAGCTGGGTCTATTTCTTTTTGCCAGAGGG 
Orf 66 for  AAAAAGCAGGCTCCGCCATGGCCCTGGATCAGCGC 
Orf 66 rev  AGAAAGCTGGGTTCAGGAGGAACACTTCCCGC 
ORF 67.5 for AAAAAGCAGGCTCCGCCATGGAGTACGCGTCTGACCA
G 
ORF 67.5 rev AGAAAGCTGGGTTCAGGGCCGTGCCCGCGC 
Orf 68 for ext  AAAAAGCAGGCTCCGCCATGTCACGAGGCAGAAGC 
Orf 68 rev ext  AGAAAGCTGGGTTTAGGCATAGTCCTCGAAGAAAC 
Orf 68 for cyt  AAAAAGCAGGCTCCGCCGCAGACCTGTGCGAGATC 
Orf 68 rev cyt  AGAAAGCTGGGTTCAAGCGTACAAGTGTGACGTC 
Orf 69 for  AAAAAGCAGGCTCCGCCATGGAGACCCCGATATGCAC 
Orf 69 rev  AGAAAGCTGGGTTTATAGGGCGTTGACAAGTGC 
K13/Orf 71 for AAAAAGCAGGCTCCGCCATGGCCACTTACGAGGTTC 
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K13/Orf 71 rev AGAAAGCTGGGTCTATGGTGTATGGCGATAG 
K12 for cyt  AAAAAGCAGGCTCCGCCAGTGGCCAGCGTGGCCCC 
K12 rev cyt  AGAAAGCTGGGTTCAGTGCGCGCCCGTTGC 
K12 for ext  AAAAAGCAGGCTCCGCCATGGATAGAGGCTTAACGGT
G 
K12 rev ext  AGAAAGCTGGGTCCTCCAGCGCCACCCATTTAG 
Orf 72 for  AAAAAGCAGGCTCCGCCATGGCAACTGCCAATAACCC 
Orf 72 rev  AGAAAGCTGGGTTTAATAGCTGTCCAGAATGCG 
Orf 73 for  AAAAAGCAGGCTCCGCCATGGCGCCCCCGGGAATG 
Orf 73 rev  AGAAAGCTGGGTTTATGTCATTTCCTGTGGAGAG 
K14 for  AAAAAGCAGGCTCCGCCATGATACACACATTTTTTGATT
G 
K14 rev  AGAAAGCTGGGTTCACTGGGTGGATAGGGG 
K14.1 for AAAAAGCAGGCTCCGCCATGCCTAGAGGGCGCACC 
K14.1 rev AGAAAGCTGGGTCTAGGACCACAGCATTTTTC 
Orf 74 for  AAAAAGCAGGCTCCGCCTCCCTCTTTAGGCAGAGGAT
G 
Orf 74 rev  AGAAAGCTGGGTCTACGTGGTGGCGCCGGAC 
Orf 75 for  AAAAAGCAGGCTCCGCCATGGCCTACGACGTCACTG 
Orf 75 rev  AGAAAGCTGGGTTTAGTGGTGGTCGTTGATC 
Orf 9 for AAAAAGCAGGCTCCGCCATGGATTTTTTCAATCCATTTA
TC 
Orf 9 rev AGAAAGCTGGGTCTAGGGCGTGGGAAAAGTC 
K15 for cyt AAAAAGCAGGCTCCGCCAAGGAAAAAAAAGTGGTGGC 
K15 rev cyt  AGAAAGCTGGGTCTAGTTCCTGGGAAATAAAACC 
Orf 22 rev ext AGAAAGCTGGGTTTAACTGGCTGCGCGTCTTC 
Orf 22 for cyt AAAAAGCAGGCTCCGCCTACAGACTGTTTTCCATC 
Orf 28 for ext AAAAAGCAGGCTCCGCCATGAGCATGACTTCCCCGTCT
CC 
Orf 28 rev ext AGAAAGCTGGGTTTAGGGAGGCTTGGTGGCCATTC 
Orf8 for ext AAAAAGCAGGCTCCGCCATGACTCCCAGGTCTAGATTG
Orf8 rev ext AGAAAGCTGGGTTTAGCCACCTAGGGGGTGTTT 
Orf 22 for ext AAAAAGCAGGCTCCGCCATGCAGGGTCTAGCCTTC 
K 8.1 for  AAAAAGCAGGCTCCGCCCAGGACCACGCGAATTCG 
K 8.1 rev  AGAAAGCTGGGTCTATTTCTGCCGTTTTCTG 
Orf 64 I rev CAGGGCGTCCAGGGCATC 
Orf 64 II for ATTAGGATCGCCTCGCGTGAG 
Orf 64 II rev CGCGTAATGCAGGGCTGG 
Orf 64 III for GTCGCGGATTATGTGGAG 
Orf 64 III rev CTTCCGTGGGTCAATGAC 
Orf 64 IV for TACCCCTACGGCCTTGCC 
Orf 64 ½ for (Kpn1) AAAAAGCAGGCTCCGCCGGTACCCCCCTGGAGCTCCC
TGCCACAG 
Orf 64 ½ rev (Kpn1) AGAAAGCTGGGTTAGGTACCCACCGTGGCCTGCTGCA
ATCG 
K3 cyt1 rev AGAAAGCTGGGTTATTCCAGACCCTCCTGGTAAG 
K3 cyt2 for AAAAAGCAGGCTCCGCCCACATGATGCGCCACGTGGG
G 
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K5 cyt1 rev AGAAAGCTGGGTTATTCAAAAATTTCTTGGCGCTCC 
K5 cyt2 for AAAAAGCAGGCTCCGCCGGCGGCATATGCCGCGTAAG
TGG 
K1 for AAAAAGCAGGCTCCGCCATGTTCCTGTATGTTGTCTGC 
K1 rev AGAAAGCTGGGTTCAGTACCAATCCACTGGTTGC 
Orf 47 for AAAAAGCAGGCTCCGCCCACTCTATCCACTTCGCC 
Orf 39 for AAAAAGCAGGCTCCGCCCATGCGCGCTTCAAAGAGCG
ACC 
K8.1 cyt for AAAAAGCAGGCTCCTACCTGTGCGTTCCACGATGC 
K8.1 rev AGAAAGCTGGGTTACACTATGTAGGGTTTCTTACG 
vIRF3 for AAAAAGCAGGCTCCGCCATGGCGGGACGCAGGCTTAC
C 
CD19 for CAGTCCTATGAGGATATGAGAGGAA 
Orf 74 for (FL) AAAAAGCAGGCTCCGCCATGGCGGCCGAGGATTTCC 
Orf 22 cyt 
(Adapter)for 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCTACA
GACTGTTTTCCATCCTTTATTAGACCCAGCTTTCTTGTA
CAAAGTGGTCCCC 
Orf 22 cyt (Adapter) 
rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTAATAAAG
GATGGAAAACAGTCTGTAGGCGGAGCCTGCTTTTTTGT
ACAAACTTGTCCCC 
Orf 53 cyt 
(Adapter)for 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCAAG
TTTGTGGACGAGGTGGTCCATGCATAGACCCAGCTTTC
TTGTACAAAGTGGTCCCC 
Orf 53 cyt (Adapter) 
rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTATGCATG
GACCACCTCGTCCACAAACTTGGCGGAGCCTGCTTTTT
TGTACAAACTTGTCCCC 
k1 ext rev AGAAAGCTGGGTTATACAAGAAAATGCACTTCAAT 
k1 cyt for  AAAAAGCAGGCTCCGCCCATTGTCAAAAACAACGTGAC
K15(Lamp,P-Allel)for AAAAAGCAGGCTCCGCCATGAAGACACTCATATTC 
Orf 57 spliced for AAAAAGCAGGCTCCGCCATGGTACAAGCAATGATAG 
Orf 75I rev(StuI) AGAAAGCTGGGTTAGTAGGCCTGCTCCCCCATGGCC 
Orf 75II for(StuI) AAAAAGCAGGCTCCGCCATGGCCAACCTCCTACACAA
G 
Orf 64 II Spe1 for AAAAAGCAGGCTCCGCCATGTGCGAGATCGTCCAACA
G 
Orf 64 I Spe1 rev AGAAAGCTGGGTTACAGGGACTTGAAGTCCTGACG 
Orf 64 IV Not1 for AAAAAGCAGGCTCCGCCATGCGGCCGCTTACTGCGGA
TGAATCCG 
Orf 64 III Not1 rev AGAAAGCTGGGTTAAAGCGGCCGCAAGGTGGACCACA
GCTGCC 
Zeo Mlu1 for CGCGGGACGCGTCGTTTACAATTTCGCCTG 
Zeo Xba1 rev CGCGGGTCTAGACTGCTGATCTTCAGATCC 
Orf 6 I Sac1 rev AGAAAGCTGGGTTAATGGACGGATTTGATGTTCTCTCT
G 
Orf 6 II Sac1 for  AAAAAGCAGGCTCCGCCATGGCAGAGCTCCTAAAGTTT
ATTAAC 
Orf 63 I Mlu1 rev AGAAAGCTGGGTTACAAGTGACTCTTGGTAAACGC 
Orf 63 II Mlu1 for  AAAAAGCAGGCTCCGCCATGCGGGCCATCTTCGAGAT
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C 
 
5.1.9.2. Other oligonucleotides used in the study 
ELK-1 forward AAA AAG CAG GCT CCG CCA TGG ACC CAT CTG TGA 
CGC 
ELK-1 reverse AGA AAG CTG GGT TCA TGG CTT CTG GGG CCC TG 
SpiB forward AAA AAG CAG GCT CCG CCA TGC TCG CCC TGG AGG 
CTG C 
SpiB reverse AGA AAG CTG GGT TCA GTA GCC CCA GCA GGA ACT G 
STAT-1 forward AAA AAG CAG GCT CCG CCA TGT CTC AGT GGT ACG AAC
STAT-1 reverse AGA AAG CTG GGT TTA CAC TTC AGA CAC AGA AAT C 
 
The oligonucleotides were obtained from Invitrogen (Germany) and Metabion 
(Martinsried, Germany). 
 
5.1.10. Plasmids 
 
5.1.10.1. Constructs used for reporter gene analysis 
The luciferase reporter constructs pAP-1-luc, pSRE-luc and pISRE-luc were purchased 
from PathDetect® in Vivo Signal Transduction Pathway cis-Reporting Systems 
(Stratagene): 
 
pAP-1-luc 7x AP-1 (TGACTAA) binding sites 
pISRE-luc 5x ISRE (TAGTTTCACTTTCCC) binding sites 
pSRE-luc 5x SRE (AGGATGTCCATATTAGGACATCT) binding sites 
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5.1.10.2. Other plasmids used in the study 
pGLMR5 GAL4-reporter kindly provided by Michael Meisterernst, GSF, 
München102  
IMAG p958D03310Q2  obtained from the Rzpd, Heidelberg 
IRAK p961L1793Q2  obtained from the Rzpd, Heidelberg 
L25 kindly provided by Thomas Schulz, Medizinische 
Hochschule Hannover157  
L26 kindly provided by Thomas Schulz, Medizinische 
Hochschule Hannover157 
mSRF-luc kindly provided by Jessica Schwartz, University of 
Michigan Medical School, Michigan89  
mTCF-luc kindly provided by Jessica Schwartz, University of 
Michigan Medical School, Michigan89  
pARC92/ACID-1 kindly provided by Michael Meisterernst, GSF, 
München102  
pARC92/ACID-1-NTD kindly provided by Michael Meisterernst, GSF, 
München102  
pcDNA3.1 zeo obtained from Invitrogen, Karlsruhe, Germany 
pcDNA3.1-LANA-1 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 
pCR3 obtained from Invitrogen, Karlsruhe, Germany 
pDEST-script kindly provided by Ulrich Hentschel 
pGADT7  obtained from BD Biosciences Clontech, 
Heidelberg, Germany 
pGAL4-VP16 kindly provided by Michael Meisterernst, GSF, 
München102  
pGAL4-VP16 H1 kindly provided by Michael Meisterernst, GSF, 
München102 
pGBKT7 obtained from BD Biosciences Clontech, 
Heidelberg, Germany 
pGEX-1 C1 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
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pGEX-1 C2 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 C4 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 C5 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 C6 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 C7 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 C8 kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 GST kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGEX-1 LANAC kindly provided by Thomas Schulz, Medizinische 
Hochschule, Hannover 116  
pGL12 kindly provided by Diane Hayward, Johns Hopkins 
School of Medicine, Baltimore 85  
pGL13 kindly provided by Diane Hayward, Johns Hopkins 
School of Medicine, Baltimore 85  
pGL9 kindly provided by Diane Hayward, Johns Hopkins 
School of Medicine, Baltimore 85  
pHIVluc  kindly provided by Michael Meisterernst, GSF, 
München 
p-IL6 -Luc kindly provided by Gergana Iotzova, Max von 
Pettenkover Institut, München 
pLANA-1-gfp kindly provided by Matthew Rettig, VA Greater Los 
Angeles Healthcare System, Los Angeles3 
pNFκB-Luc obtained from Stratagene, Amsterdam, The 
Netherlands 
pRK5c-mycRasV12  kindly provided by Dr.Alan Hall, MRC, London, UK 
pSpiB kindly provided by Celeste Simon, Department of 
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Medicine, University of Chicago151  
pSV2tat72  NIH AIDS reagent program 
wtSRE-luc kindly provided by Jessica Schwartz, University of 
Michigan Medical School, Michigan89  
 
 
5.1.11. Molecular weight markers 
 
5.1.11.1. Markers for measurements of protein size 
See blue 2 prestained protein standard low range obtained from Invitrogen, Karlsruhe, 
Germany. 
 
5.1.11.2. Markers for measurements of DNA size 
Gene Ruler 100 bp DNA ladder obtained from MBI Fermentas, Germany 
Gene Ruler DNA 1 kb ladder obtained from MBI Fermentas, Germany 
 
5.1.12. Kits 
NucleofectorTM Transfection Kit  Amaxa, Biosystems, Germany 
ECL Western blotting detection system   Amersham-Pharmacia, Germany 
Pharmacia GFX PCR DNA Gel 
Purification Kit   
Amersham-Pharmacia, Germany 
Nucleobond AX® Plasmid DNA Purification 
Kit  
Macherey-Nagel, Germany 
Nucleobond AX® BAC DNA Purification Kit  Macherey-Nagel, Germany 
BCA Protein  Assay Pierce, Rockford, USA 
Luciferase Assay System   Promega, Mannheim, Germany 
Dual-Luciferase®Reporter Assay System  Promega, Mannheim, Germany 
Effectene Transfection Reagent Qiagen, Hilden,Germany 
Qiafilter Plasmid Maxi Kit  Qiagen, Hilden, Germany 
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5.1.13. Antibodies 
Primary antibody Clone/Catalogue 
number 
Company/Provider 
Goat polyclonal α-SpiB  sc-5947 x Santa Cruz 
Mouse monoclonal α-GST 
monoclonal (B-14)  
sc-138 Santa Cruz 
Mouse monoclonal α-myc (9E10)  sc-40 Santa Cruz 
Mouse monoclonal α-human Sur-2  550429 BD Pharmingen 
Rabbit α- caspase 3 9662 Cell Signaling 
Rabbit α-actin A-2066 Sigma 
Rabbit polyclonal α-ELK-1* 9181s Cell Signaling 
Rabbit polyclonal α-ELK1-1 9182 Cell Signaling 
Rabbit polyclonal α-GFP sc-8334 Santa Cruz 
Rabbit polyclonal α-human SRF 
against C-terminal domain  
sc-335 Santa Cruz 
Rabbit polyclonal α-MEK1/2 9122 Cell Signaling 
Rabbit polyclonal α-MEK1/2* 9121 Cell Signaling 
Rabbit polyclonal α-STAT-1 9172 Cell Signaling 
Rabbit polyclonal α-STAT-1* 9171s Cell signaling 
Rat α-KS 330A  4F8-1 E. Kremmer 
Rat α-KSHV ORF25 
KSB 330B IgG2a (2003) 
4G2-1-5-1 E. Kremmer 
Rat monoclonal α-ARC92/ACID-1  (9C2) M. Meisterernst 
E. Kremmer 
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Rat monoclonal α-HA tag 1867423 Roche 
Rat monoclonal α-human Mediator7 Med7 M. Meisterernst 
E. Kremmer 
Rat monoclonal α-KSHV ORF73 
against latent nuclear antigen 
LANA-1  
13-210-100 ABI 
Rat monoclonal α-PCQAP  (6C9) M. Meisterernst 
E. Kremmer 
α-goat-POX 305035003 Dianova 
α-human-POX 109035088 Dianova 
α-mouse-POX 115035146 Dianova 
α-rabbit-POX 111035144 Dianova 
α-rat-POX 112035062 Dianova 
 
* recognizes the phosphorylated forms of the protein 
POX - peroxidase-conjugated antibodies  
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5.2. Methods 
 
5. 2. . Bacteria related methods 
 
5.2.1.1. Preparation of competent E. coli 
50 ml LB medium were inoculated with 0.5 ml overnight culture of E. coli DH5α or 
DH10B and grown to A600 of 0.5. The bacteria were then centrifuged in a 50 ml conical 
tube (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ) at 3000 rpm, 5 min, 4°C, 
resuspended in 25 ml cold sterile 0.1 M CaCl2 and stored on ice for 30 min. After a 
second centrifugation as above, the bacteria were resuspended in 1 ml cold 0.1 M CaCl2 
and frozen in 15 % sterile glycerol at –80°C, in aliquots. 
 
5.2.1.2. Transformation and growth of transformed bacteria 
For the transformation of E. coli either chemically competent bacteria or 
electrocompetent bacteria were used depending on the DNA (ligation mix, plasmid, BAC 
DNA, etc.). 
 
100 µl of the chemical competent bacteria were mixed with 0.1–100 ng of plasmid DNA 
and incubated on ice for 30 min. The cells were heat shocked by placing in a 42°C water 
bath for 90 s. 1 ml LB medium was added to the transformation mix and the tubes were 
placed in a 37°C shaker for 1 h. Afterwards the bacteria were spread onto LB agar 
plates containing the respective antibiotic: 100 µg/ml ampicillin, 50 µg/ml kanamycin, or 
34 µg/ml chloramphenicol and grown overnight at 37°C. Single colonies were used to 
inoculate 2 ml LB cultures. These cultures were expanded to 400 ml and grown 
overnight at 37°C, shaking at 200 rpm.  
 
100 µl of the electrocompetent bacteria were mixed with the ligation mixture or plasmid 
DNA and incubated on ice for 10 min. Then the bacteria were placed in a 2 mm Gene 
Pulser® cuvette (Bio-Rad Laboratories, Hercules, CA) and a pulse of 2.5 kV and 25 µF 
was applied. The next steps were as for the chemical competent bacteria described 
above. 
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5.2.1.3. Preparation of glycerol stocks 
Bacterial overnight cultures were mixed 1:1 with 50 % glycerol to an end concentration 
of 20 % (v/v) and stored in 1 ml aliquots at –80°C. 
 
5.2.2. Methods for DNA isolation, purification and analysis 
 
5.2.2.1. “Mini” and “maxi” plasmid preparation 
Maxi preps were done using kits from Qiagen (Chatsworth, CA) according to the 
manufacturer’s instructions. Mini preps were done according to Sambrook et al. 
(Molecular Cloning, A Laboratory Manual, 1989). 
 
5.2.2.2. Restriction digests 
Restriction digests were typically incubated for 2 h at 37°C with 5-10 units restriction 
endonuclease per µg DNA in the appropriate buffer as recommended by the 
manufacturer (New England Biolabs, Beverly, MA). 
 
5.2.2.3. Ligation 
To avoid religation of incompletely digested vector, 5’ ends were dephosphorylated by 
calf intestinal alkaline phosphatase (CIP). 50 U CIP were used for dephosphorylation of 
about 1 µg vector DNA. The reaction was performed for 40 min at 37°C and afterwards 
blocked. Then the CIP-ed vector was mixed with the purified fragment. Approximately 
40-60 ng vector DNA was used. The molar ratio of vector/insert was between 1:3-1:8 
(depending on the size of the fragment). The reaction was performed in a total volume of 
30 µl 1x reaction buffer (MBI Fermentas) with 5 to 10 U T4 DNA ligase (MBI Fermentas). 
First vector and insert were mixed in reaction buffer subsequently the ligase was added. 
After incubation overnight in a water bath at 16°C the ligation was either directly 
transformed into competent bacteria or stored at –20°C until further usage. 
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5.2.2.4. Polymerase chain reaction (PCR) 
The standard PCR reaction is assembled by mixing the following components:  
Reagent Amount 
DNA 2-200 ng 
10× PCR buffer 5 µl 
25 mM MgCl2 5 µl 
dNTPs (10 mM) 2 µl 
Primers (forward and reverse) 20 pmol (each) 
Polymerase 0,5 µl 
ddH2O up to final volume 50µl 
 
In most cases the following program was used: 94°C for 5 min (or 2 min depending on 
the enzyme used); 94°C for 1 min, 54°C for 30 sec, 72°C for 1 min 30 sec (or longer); 
72°C for 7 min. 
 
5.2.2.5. Agarose gel electrophoresis 
Agarose (electrophoresis grade, GibcoBRL, Grand Island, NY) was dissolved in 0.5x 
TBE buffer to the desired concentration (1 to 2.5 % depending on the size of DNA 
fragments) by boiling in a microwave oven. After cooling down, ethidium bromide was 
added to a final concentration of 0.5 µg/ml and the agarose solution poured in a gel 
chamber (Peqlab Biotechnologie GmbH, Erlangen). The DNA sample was mixed 1:10 
with 10x DNA sample buffer (30 % glycerol, 0.25 % Bromphenol Blue, 0.25 % Xylene 
Cyanole in TBE buffer). The gels were run in 0.5xTBE buffer and visualized on a UV 
transilluminator. 
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5.2.2.6. Purification of DNA from agarose gel  
DNA was purified from agarose gel according to the protocol from the manual of GFX-
TM PCR DNA and Gel Band Purification Kit (Pharmacia). 
 
5.2.2.7. Recombinatorial cloning - generation of a KSHV array in the eukaryotic 
expression vector pDEST-script  
The KSHV array was generated into the eukaryotic expression vector pDEST-script (B-
cassette) using the GATEWAY cloning technology. The recombination reactions of the 
GATEWAY cloning technology are based on the site specific recombination reactions by 
endonucleases and ligase of bacteriophage λ in E. coli. The LR reaction is a 
recombination reaction between an entry clone (pDONR207) and a destination vector 
(pDEST-script-B-cassette), mediated by the LR clonase mix of recombination proteins. 
Previously, all the KSHV ORFs have been cloned into the entry vector pDONR207 
(Invitrogen) (Uetz et al., unpublished). In this project, all the ORFs of the KSHV genome 
were subsequently subcloned into the destination vector pDEST-script (B-cassette). The 
B-cassette containing the two recombination sites, attR1 and attR2, flanking a 
chloramphenicol resistance (CmR) gene and a ccdB gene were previously included into 
pCMV-script vector in EcoRV unique site converting it into a Gateway destination vector. 
The subcloning was done according to the manufacture’s protocol (Gibco BRL, 
Invitrogen, Life Technologies) with small modifications. 200 ng from each donor (entry) 
vector containing ORF of KSHV were mixed with 300 ng from the destination vector 
pDEST-script. 1 µl LR buffer, 1 µl LR clonase mix and 1 µl DNA topoisomerase I (10 
U/µl-MBI Fermentas) were added, mixed well and left at RT for 1 h or overnight 
(depending on the size of the fragments for subcloning). The total volume of the reaction 
mix was between 5 and 8 µl. After 1 h (or overnight incubation) the LR reaction was 
stopped by adding 2 µl proteinase K (Gibco BRL, Invitrogen, Life Technologies) and 
incubating for 10 min at 37°C. Next step was to transform bacteria (electrocompetent 
DH10B or DH5α) with 1 µl from the LR mix. After 1h incubation in 1 ml SOC medium or 
LB at 37°C in a shaker 150 µl of the bacterial culture was plated on kanamycin plates 
and left overnight at 37°C for selection of positive clones. The next day 3 to 5 bacteria 
colonies were picked up, minipreps were performed and the DNA was checked by 
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restriction digest. One of the positive clones was then used to perform a maxiprep of 
DNA, which was kept at –20°C. 
 
5.2.2.8. Generation of constructs expressing transcription factors using 
recombinatorial cloning 
The transcription factors STAT-1, ELK-1 and SpiB were generated as PCR products 
using primers specific for each transcription factor carrying the attB sites. The templates 
used were IMAG p958D03310Q2 (rzpd) for STAT-1, IRAK p961L1793Q2 (rzpd) for 
ELK-1 and pSpiB expression vector for SpiB. The following primers were used: STAT-1 
forward, STAT-1 reverse, ELK-1 forward, ELK-1 reverse, SpiB forward and SpiB reverse 
the sequences of which are indicated in Materials and Methods.  
The PCR was done in two steps. The first PCR were performed using primers specific 
for each transcription factor with the following program: 1x 2.5 min 94°C; 10-15 cycles: 
15 sec 94°C; 60 sec 55°C; 15-180 sec (60 sec per 1000 bp) 72°C (hot start: add 
polymerase added after 2.5 min 94°C denaturation). The second PCR step was done 
using the same pair of external primers for each transcription factor namely attB1 
external forward and attB2 external reverse. The sequences are indicated in Materials 
and Methods. 
The PCR program was carried out using the following scheme: 5 cycles 15 sec 94°C; 30 
sec 45°C; 15-180 sec (60 sec per 1000 bp) 68°C 10-15 cycles 15 sec 94°C; 30 sec 
55°C; 15-180 sec (60 sec per 1000 bp) 68°C. The PCR products were than run on a 1 % 
agarose gel and purified by GFX-TM PCR DNA and Gel Band Purification Kit 
(Amersham-Bioscience). The purified PCR products were cloned into pDONR207 vector 
by BP clonase reaction and subsequently subcloned into destination vector pGBKT7 by 
LR clonase reaction. 
 
5.2.2.9. Generation of the pGADT7-LANA-1 expression construct 
LANA-1 was first cloned into pDONR207 and subsequently into pGADT7 by 
recombinatorial cloning.  
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5.2.3. Tissues culture and related techniques 
 
5.2.3.1. Culture conditions 
The cell lines used in this study were grown in the following media:  
 
HeLa and HEK 293 cells: Dulbecco’s modified Eagle medium (DMEM), containing 1 g/l 
glucose and supplemented with 10 % FCS, 4 mM L-glutamine, 100 units/ml penicillin G 
and 100 µg/ml streptomycin sulfate (Invitrogen Life Technologies). 
 
Jurkat, BJAB, LCLs, DG75 and BCBL-1: RPMI 1640 medium, supplemented with 20 
% heat-inactivated fetal calf serum (FCS) and 100 U/ml penicillin G, 100 µg/ml 
streptomycin sulfate, 4 mM L-glutamine. 
The adherent cell lines used in this study were usually grown in 10-cm or 15-cm tissue 
culture dishes (Falcon, Becton Dickinson Labware) in a tissue culture incubator with 5 % 
CO2 atmosphere at 37°C. Subculturing of the adherent cells was done by trypsinization 
with 0.25 % trypsin, 0.2 % EDTA (Invitrogen Life Technologies).  
Suspension cell lines were grown in 25, 75 or 175 cm2 tissue culture flasks. Subculturing 
of suspension cells was done by diluting with fresh medium.  
 
5.2.3.2. Cryoconservation 
Cells were frozen in 90 % FCS and 10 % (v/v) dimethyl-sulfoxide (DMSO) in a freezing 
box at -80°C. The frozen aliquots were first stored at –80°C and subsequently in a liquid 
nitrogen tank.   
Thawing of the cells was done by submerging the frozen vial in a 37°C water bath. The 
cells were then washed with medium by centrifugation at 1200 rpm for 3 min and 
resuspended in pre-warmed medium before transferring them to culture plates or flasks. 
 
5.2.3.3. Lipofection 
HEK 293 cells or HeLa cells were split into 6, 24 or 48 - well plates the day before 
transfection. The plasmid DNAs were transiently transfected using Effectene (Qiagen) 
according to the protocol in the manual. One day post transfection the DMEM was 
replaced with fresh medium containing 1 % fetal calf serum (FCS) and supplements, and 
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cells were starved for another 24 h. After 48 h cells were harvested, lysed in 1x passive 
lysis buffer and luciferase activity was measured by using a commercial luciferase assay 
system (Promega) and a tube luminometer (Berthold). The transfection efficiency was 
normalized by co-transfection of the RL-TK vector (Promega) containing Renilla 
luciferase.  
 
5.2.3.4. Calcium phosphate transfection 
One day before transfection HEK 293 were seeded in 10 cm tissue culture dishes at 30 
% confluency. 10 µg total DNA was used, 500 µl 2.5 M CaCl2 was added, the tubes 
were vortexed, and left at room temperature for 5 min. 500 µl of 2x HEBS were added 
dropwise while gently vortexing, and the solution was incubated another 20 min at room 
temperature. Calcium phosphate-DNA solution was added dropwise onto the cell culture 
plate while swirling. The plates were incubated overnight in a 5 % CO2-humidified 
incubator at 37°C. On the next day the medium was exchanged with fresh MDEM 
medium containing 1 % FCS and the cells were starved for another 24 h. 48 h after 
transfection the cells were harvested and lysed in the appropriate lysis buffer. 
 
5.2.3.5. Transfection by electroporation  
For electroporation of cells, 5×106 cells per transfection were spun down and 
resuspended in 400 µl pre-warmed FCS. 40 µg total plasmid DNA (the total DNA 
concentration in each transfection experiment was kept constant by adding vector 
plasmid DNA) was added to the cell suspension and mixed carefully. The sample was 
transferred to a 4 mm Gene Pulser® cuvette (Bio-Rad Laboratories, Hercules, CA) and a 
pulse of 250 mV and 1200 µF was applied. The cell suspension was then transferred to 
a 10 cm tissue culture dish, containing 10 ml pre-warmed RPMI medium and the cells 
were incubated for the desired period of time (at least 36 h).  
This protocol was applied successfully for the transfection of Jurkat, BJAB and DG75 
cells. 
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5.2.3.6. Luciferase reporter assays 
Cells were collected, washed once with 1x PBS and resuspended in 100 µl 1x Passive 
Lysis Buffer (Promega, Madison, WI). The cell suspension was incubated 15 min at 
room temperature. The cell debris were spun down at 13000 rpm for 5 min 20 µl of the 
protein extract was used for measurement of luciferase activity using the Dual 
Luciferase assay system (Promega, Madison, WI), following the manufacturer’s 
instructions. The measurement was performed with the luminometer LUMAT LB9507 
(EG&G® BERTHOLD, Wellesley, MA). 
 
5.2.3.7. Stimulation/inhibition of cell signal transduction pathways 
For the transfection experiments with stimulation of main signal transduction pathways 
the following chemicals were used: 
IFN α or IFN β activate the type I interferon-mediated pathway. They were used at a 
concentration of 500 U/ml. 
TPA activates protein kinase C in vivo and in vitro. Active concentration 20 ng/ml. 
Ionomycin is a Ca2+ ionophore, a mobile ion carrier for Ca2+, which induces apoptotic 
degeneration. It was used at a concentration of 20 ng/ml.  
For transfection experiments, inhibitors were added, 10 h before harvesting the cells, at 
the concentration mentioned below. The following inhibitors were used: 
PD98059 (MEK1 inhibitor) inhibits phosphorylation activation of MEK1 by upstream 
kinases. Active concentration 10-20 µM. 
U0126 (MEK1/2 inhibitor) inhibits phosphorylation activation of MEK1 and MEK2 by 
upstream kinases. Active concentration 10-20 µM. 
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5.2.4. Protein purification and analysis 
 
5.2.4.1. Cell extracts 
Plates of adherent cells were washed twice with Dulbecco’s PBS, scraped off with a 
rubber policeman and transferred to an Eppendorf tube. Suspension cells were collected 
by centrifugation, washed twice in Dulbecco’s PBS without Ca2+ and Mg2+, and 
transferred to Eppendorf tubes. All subsequent steps were performed on ice. The cells 
were resuspended in an appropriate volume (depending on the cell pellet) NP-40 lysis 
buffer: 1 % NP-40, 140 mM NaCl, 5 mM MgCl2, 20 mM Tris pH 7.6 and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) (freshly added). The samples were incubated on 
ice for 20 - 30 min and then centrifuged for 15 min at 13000 rpm, 4 °C. The supernatant, 
containing the total protein extract, was transferred to a fresh Eppendorf tube and the 
total protein extract was stored at –20°C or –80°C. 
 
5.2.4.2. Nucleic extracts preparation 
All steps were done at 4°C or on ice! First, the cells were washed in cold 1x PBS. Then 
they were resuspended in 200 µl buffer A (1 mM PMSF, 1 mM DTT, 0.4 mM NaVan, 1 
mM NaF) and incubated for 15 min on ice. Afterwards 12 µl TRITON-100 (10 %) was 
added and the tube was vortexed. After 1 min the cells were centrifuged for 5 min at 
2000 rpm. The nuclei were washed 2 times with 500 µl buffer A (plus inhibitors) and 
centrifuged for another 2 min at 4°C at 1750 rpm. Next the nuclei were resuspended in 
200 µl buffer C (plus inhibitors) and rolled at 4°C for 15 min. Finally, a centrifugation for 
10 min at 4°C at 14 000 rpm was done, the supernatants were collected in new tubes 
and stored at –80°C. 
 
5.2.4.3. Measurement of protein concentration 
The protein concentration was determined using the Bradford assay (Pierce). 
 
5.2.4.4. Western blotting (immunoblotting) 
Proteins separated by SDS-PAGE were transferred on a nitrocellulose filter (membrane) 
by either wet or semi-dry blot transfer.  
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For semi-dry transfer the ROTH „SEMI-DRY-BLOT“ apparatus was used applying 
constant current of 0.8 mA per cm2 for 1 h. For protein transfer, the gel was sandwiched 
between gel-sized Whatmann 3 MM papers soaked in transfer buffer (20 % methanol in 
1× Tris/glycine buffer). 
The wet blot was carefully set up under transfer buffer to avoid air pockets. The transfer 
was run in a cold room at 100 V for 1 h and 30 min or at 40 V overnight.  
After transfer, nitrocellulose filters were incubated for 1 h in a Blocking solution (TBS 
containing 5 % milk powder and 0.1 % Tween-20) in order to reduce the unspecific 
background. The membrane was sealed in a plastic bag and incubated for 1 h with an 
appropriate dilution of the primary antibodies, directed against the protein of interest.  
The membrane was washed 3 times for 10 min in TBST (0.1 % Tween-20 in TBS) and 
incubated for an additional 1 h with the appropriate secondary antibody conjugated to 
horseradish peroxidase. After 3 washes in TBST, antigen-antibody complexes were 
detected using the enhanced chemiluminescence detection system (NEN, Boston, MA 
or Amersham Biosciences), according to the manufacturer’s instructions and exposed 
on Biomax-MR film (Eastman Kodak, Rochester, NY). 
 
5.2.4.5. Co-immunoprecipitation  
Co-immunoprecipitation (CoIP) was performed using lysates from HEK 293 cells 
transfected with the expression plasmids pcDNA-LANA-1 and pLANA-1-gfp for LANA-1 
and expression plasmid pARC92/ACID-1 for the Mediator protein ARC92/ACID-1. HEK 
293 cells were cultured in 10 cm dishes and transfected with 10 µg of each of the two 
expression plasmids by the calcium phosphate transfection method. Expression was 
controlled using a GFP plasmid under the control of a T7. After 24 h, the medium was 
changed with fresh medium containing 1 % FCS and the cells were starved for another 
24 h. After 48 h they were harvested and lysed by incubation for 30 min in 1 ml of NP-40 
lysis-buffer (1 % NP-40, 140 mM NaCl, 5 mM MgCl2, 20 mM Tris pH 7,6, 1 mM PMSF) 
on ice. Lysates were centrifuged for 15 min at 20,000 g and 4°C to remove unsolubilized 
material and pre-cleared with 25 µl of protein G-sepharose (Pharmacia) for 1h at 4°C. 
Beads were washed three times with ice-cold 1x PBS. Proteins were precipitated 
respectively from the monoclonal rat anti-ORF73 antibody, anti-ARC92/ACID-1 and anti-
PCQAP for 4 h. Subsequently, new precleared 30 µl of protein G-sepharose beads (30 
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µl per sample) were added and incubated overnight at 4°C. Co-immunoprecipitations 
and transfected HEK 293 cells were resuspended in 2x SDS protein sample buffer. 
Samples were boiled for 5 min, electrophoresed in 7.5 to 10 % SDS-PAGE gels and 
transferred onto nitrocellulose (Schleicher and Schuell). Protein bands were visualized 
with peroxidase-conjugated secondary antibodies and enhanced chemiluminescence 
(Pharmacia). 
 
5.2.4.6. Co-immunoprecipitation using recombinant vaccinia virus (vT7) 
Co-immunoprecipitations between LANA-1 (in pGADT7) and the transcription factors 
ELK-1, STAT-1 and SpiB (all in pGBKT7) were performed using total cell lysates of HEK 
293 cells transfected using recombinant vaccinia virus vT7 expressing the T7 RNA 
polymerase. HEK 293 cells were cultured on 10 cm dishes and infected with vT7 at a 
MOI of 10 in serum-free medium. The cells were incubated at 37°C for 1 h and 30 min. 
Immediately after infection cells were transfected with 10 µg of each of the two 
expression plasmids by calcium phosphate transfection (as described above) and were 
harvested 24 h post-transfection. 
 
5.2.4.7. Measuring of p44/42 MAP Kinase Activity 
For measuring MAP kinase activity the non-radioactive method from Cell Signaling 
Technology has been used. The assay was performed according to the protocol in the 
manual (p44/42 MAP Kinase Assay Kit, Cell Signaling Technology). Briefly, the cells 
were lysed and active (phosphorylated) MAPK was precipitated using immobilized 
antibody from the kit. The IP pellets were incubated in kinase buffer containing ELK-1 
fusion protein and cold ATP and then the ELK-1 phosphorylation at Ser383 was 
analysed by WB and chemiluminescent detection using phospho-antibodies. 
 
5.2.4.8. Coomassie blue staining 
The protein lysates to be analysed were loaded on SDS-PAGE gels and incubated for 
30 min with Coomassie blue staining solution: 0,25 % Coomassie brilliant blue R-250, 45 
% methanol, 10 % acetic acid. Afterwards they gel was destained by several washes 
with 10 % methanol, 10 % acetic acid solution until the desired protein staining was 
visible.  
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5.2.4.9. Purification of GST-tagged fusion proteins, binding reaction 
1ml of overnight culture of BL21 transformed with constructs expressing GST-fusion 
proteins was inoculated into 9 ml of fresh LB containing ampicillin (100 µg/ml) and 
incubated for 1 h at 37°C. IPTG was added to a final concentration of 1 mM and 
incubated for an additional 3 - 4 h at 30°C. The bacteria were harvested at 4°C by 
centrifugation for 15 min at 5000 rpm. The pellet was dissolved in 500 µl PBS contaning 
1 mM PMSF and 4 mM Pefablock and sonicated 3 times for 5 sec (output control level 
7, 100 %) with a Branson Sonifier 450. Triton X-100 was added to a final concentration 
of 1 %, solutions were mixed and centrifuged at 4°C for 10 min at 14000 rpm. The 
supernatants were retained and mixed with 50 % slurry of glutathione beads washed 
previously 3x with PBS. The protein lysates were incubated with the glutathione beads 
for 30 min at RT. The beads were then centrifuged and washed 3 times with washing 
buffer (50 mM Tris pH 7.8, 150 mM NaCl, 0.5 mM EDTA, 0.1 % NP40). For the analysis 
of protein expression by Coomassie blue 2x protein lysis buffer was added and the 
samples were boiled at 95°C for 10 min. For the pull-down assays the beads were mixed 
with the cell lysates of HEK 293 cells obtained from one 10cm culture dish and 
incubated for 1 h at RT. Subsequently, the beads were centrifuged, washed 3x with 
washing buffer and boiled for 10 min at 95°C in 2x protein lysis buffer. The binding 
reaction was analysed by Western blot analysis. 
 
5.2.5. Sequence analysis  
Protein and DNA sequences were retrieved from the NCBI GenBank Entrez server 
(http://www.ncbi.nlm.nih.gov/Entrez/) and analysed for open reading frames (ORF) and 
restriction sites using the DNA Strider software (Douglas, 1995). Sequence homology 
searches and alignments were done on the BLAST server 
(http://www.ncbi.nlm.nih.gov/BLAST/; Altschul et al., 1997). The analysis of promoters 
was performed with the Gene2Promoter algorithm (Genomatix, Münich). 
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7. Abbreviations 
 
°C  degree Celsius 
µ  micro (10-6) 
Å  Angström 
AIDS  aquired immune deficiency syndrome 
AP-1  activator protein 1 
APS  ammonium persulfate 
ARC92/ACID-1 Human activator-recruited cofactor 
ATP  adenosine triphosphate 
BAC bacterial artificial chromosome 
BCBL-1  body cavity-based lymphoma cell line 1 
bp  base pair 
C cytosine 
CmR chloramphenicol resistance 
DMEM  Dulbecco’s modified Eagle medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleoside triphosphate 
DTT  dithiothreitol 
E. coli  Escherichia coli 
e.g.  exempli gratia (Lat. = for instance) 
E1A adenoviral transcriptional activator 
EBV Epstein Barr Virus 
EDTA  ethylenediamine tetraacetic acid 
eGFP  enhanced green fluorescent protein 
et al.  et alii (Lat. = and others) 
EtOH  ethanol 
f.l.  full length 
FCS  fetal calf serum 
Fig.  figure 
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g  gram 
G guanine 
GTFs general transcription factors 
h  hour(s) 
HAV hepatitis A virus 
HBV hepatitis B virus 
HBx HBV X protein 
hCMV  human cytomegalovirus 
HDAgs HDV antigens  
HDV hepatitis D virus 
HeBS HEPES-buffered saline solution 
HEPES  2-[4-(2-Hydoxyethyl)-1-piperazinyl]-ethane 
sulfonic acid 
HHV-8  human herpesvirus-8 
His Histidine 
HIV  human immunodeficiency virus 
HSV  herpes simplex virus 
HTLV-1 human T-cell leukemia virus type 1 
HUVEC human umbilical vein endothelial cells 
IF  immunofluorescence 
IFN  interferon 
IgG  immunglobulin G 
IL  interleukin 
IP  immunoprecipitation 
IPTG  isopropylthiogalactoside 
IRD internal repeat domain 
ISRE IFN-stimulated response element 
kb  kilo bases 
kbp  kilo base pairs 
kd  kilodaltons 
KS  Kaposi’s Sarcoma 
KSHV  Kaposi’s Sarcoma associated herpesvirus 
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L  liter 
LANA-1 Latency-Associated Nuclear Antigen 1 
LANA-2 Latency-Associated Nuclear Antigen 2 
LB  Luria-Bertani 
LBS LANA-1 binding site 
LPS lypopolysaccharide 
LTR  long terminal repeats 
m  milli (10-3) 
m  meter 
M  mol/liter, molar 
MAPK mitogen-activated protein kinase 
MCD  multicentric Castleman’s disease 
MCMV  murine cytomegalovirus 
MCP  major capsid protein 
MeCP2 methyl CpG binding protein  
mHV-68 mouse herpesvirus 68 
min  minute(s) 
n  nano (10-9) 
NFkB  nuclear factor κB 
NLS  nuclear localization signal 
NTD N-terminal domain of ARC92/ACID-1 
o/n  overnight 
OD  optical density 
ORF  open reading frame 
p  pico (10-12) 
PACs bacteriophage P1-derived artificial chromosome 
PAGE  polyacrylamide gel electrophoresis 
PBS  phoshate buffered saline 
PCR  polymerase chain reaction 
PEL  primary effusion lymphoma 
PMSF  phenylmethylsulfonfluoride 
R receptor 
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RB retinoblastoma 
RNA  ribonucleic acid 
rpm  revolutions per minute 
RPMI  Rosswell Park Memorial Institute 
RT  room temperature 
SAPK stress-activated protein kinase 
SCIP small capsomer interacting protein 
SDS  sodium dodecylsulfate 
sec  second(s) 
Ser serine 
SH3 domain  Src homology 3 domain 
SRE serum response element 
SRF serum response factor 
Sur-2 Suppressor of ras protein 
SV-40  Simian virus 40 
TAE  Tris-Acetate-EDTA 
TBE Tris/borate/EDTA 
TBST  Tris buffered saline with Tween 20 
TCF ternary complex factor 
TEMED  N, N, N’, N’-tetramethylenediamine 
TF transcription factor 
TNF-α tumor necrosis factor- α 
TPA  12-O-tetradecanoylphorbol-13-acetate 
TRI-1 triplex-1 
Tris  Tris(hydroxymethyl)aminomethan 
ts temperature-sensitive 
U  unit(s), enzyme activity 
UV  ultraviolet 
V  Volt 
v/v  volumen/volumen 
v-FLIP viral FAS-ligand IL-1 β-converting enzyme 
inhibitory protein 
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VP16 virion protein of herpes simplex virus  
vT7 recombinant vaccinia virus T7 
VWA Willebrand factor type A 
VZV  varicella zoster virus 
w/v  weight/volumen 
WB  Western blot 
WDSV Walley dermal sarcoma virus 
wt  wild type 
YACs yeast artificial chromosomes 
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